UNITED STATES | ||
SECURITIES AND EXCHANGE COMMISSION | ||
WASHINGTON, D.C. 20549 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||||||||||||||||||||
, | , | , | ||||||||||||||||||||||||||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item | Page | |||||||
March 31, 2024 | December 31, 2023 | ||||||||||
(unaudited) | |||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Restricted cash and restricted investments | |||||||||||
Accounts receivable, net (1) | |||||||||||
Prepaid expenses and other current assets | |||||||||||
Total current assets | |||||||||||
Restricted cash and restricted investments | |||||||||||
Investments and equity method investees | |||||||||||
Property and equipment, net | |||||||||||
Right-of-use assets - operating | |||||||||||
Prepaid expenses and other noncurrent assets | |||||||||||
Contract cost assets | |||||||||||
Intangible assets, net | |||||||||||
Goodwill | |||||||||||
Total assets | $ | $ | |||||||||
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY | |||||||||||
Liabilities | |||||||||||
Current liabilities: | |||||||||||
Accounts payable (1) | $ | $ | |||||||||
Accrued liabilities (1) | |||||||||||
Operating lease liability - current | |||||||||||
Accrued compensation and employee benefits | |||||||||||
Deferred revenue | |||||||||||
Reserve for claims and performance - based arrangements | |||||||||||
Total current liabilities | |||||||||||
Long-term debt, net | |||||||||||
Other long-term liabilities | |||||||||||
Tax receivables agreement liability | |||||||||||
Operating lease liabilities - noncurrent | |||||||||||
Deferred tax liabilities, net | |||||||||||
Total liabilities | |||||||||||
Commitments and Contingencies (See Note 10) | |||||||||||
Mezzanine Equity | |||||||||||
Preferred class A common stock - $ | |||||||||||
Shareholders' Equity | |||||||||||
Class A common stock - $ | |||||||||||
Additional paid-in-capital | |||||||||||
Accumulated other comprehensive loss | ( | ( | |||||||||
Retained earnings (accumulated deficit) | ( | ( | |||||||||
Treasury stock, at cost; | ( | ( |
Total shareholders' equity | |||||||||||
Total liabilities, mezzanine equity and shareholders' equity | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenue(1) | $ | $ | |||||||||
Expenses | |||||||||||
Cost of revenue (1) | |||||||||||
Selling, general and administrative expenses (1) | |||||||||||
Depreciation and amortization expenses | |||||||||||
Change in fair value of contingent consideration | |||||||||||
Total operating expenses | |||||||||||
Operating loss | ( | ( | |||||||||
Interest income | |||||||||||
Interest expense | ( | ( | |||||||||
Gain from equity method investees | |||||||||||
Change in tax receivables agreement liability | ( | ( | |||||||||
Other income (expense), net | ( | ||||||||||
Loss before income taxes | ( | ( | |||||||||
Provision for (benefit from) income taxes | ( | ||||||||||
Loss before preferred dividends and accretion of Series A Preferred Stock | ( | ( | |||||||||
Dividends and accretion of Series A Preferred Stock | ( | ( | |||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | ( | $ | ( | |||||||
Loss per common share | |||||||||||
Basic and diluted | $ | ( | $ | ( | |||||||
Weighted-average common shares outstanding | |||||||||||
Basic and diluted | |||||||||||
Comprehensive loss | |||||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | ( | $ | ( | |||||||
Other comprehensive loss, net of taxes, related to: | |||||||||||
Foreign currency translation adjustment | ( | ||||||||||
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | $ | ( | $ | ( |
For the Three Months Ended March 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mezzanine Equity | Shareholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock | Class A Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings (Accumulated Deficit) | Treasury Stock | Total Shareholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2023 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested, net of shares withheld for taxes | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Performance stock units vested, net of shares withheld for taxes | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | — | — | — | — | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||||||
For the Three Months Ended March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mezzanine Equity | Shareholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock | Class A Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings (Accumulated Deficit) | Treasury Stock | Total Shareholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | $ | $ | $ | ( | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested, net of shares withheld for taxes | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Performance stock units vested, net of shares withheld for taxes | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Leveraged stock units vested, net of shares withheld for taxes | — | — | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for acquisition | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Class A common stock issued for payment of earn-outs | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of series A preferred stock, net of issuance costs | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Net income attributable to common shareholders of Evolent Health, Inc. | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2023 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Cash Flows Provided by (Used In) Operating Activities | |||||||||||
Net loss before preferred dividends and accretion of Series A preferred stock | $ | ( | $ | ( | |||||||
Adjustments to reconcile net loss to net cash and restricted cash provided by (used in) operating activities: | |||||||||||
Change in fair value of contingent consideration | |||||||||||
Gain from equity method investees | ( | ( | |||||||||
Depreciation and amortization expenses | |||||||||||
Stock-based compensation expense | |||||||||||
Deferred tax provision | ( | ||||||||||
Amortization of contract cost assets | |||||||||||
Amortization of deferred financing costs | |||||||||||
Change in tax receivables agreement liability | |||||||||||
Right-of-use operating assets | |||||||||||
Other current operating cash outflows, net | ( | ||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||
Accounts receivable, net and contract assets | |||||||||||
Prepaid expenses and other current and non-current assets | ( | ||||||||||
Contract cost assets | ( | ( | |||||||||
Accounts payable | ( | ( | |||||||||
Accrued liabilities | |||||||||||
Operating lease liabilities | ( | ( | |||||||||
Accrued compensation and employee benefits | ( | ( | |||||||||
Deferred revenue | |||||||||||
Reserve for claims and performance-based arrangements | ( | ( | |||||||||
Other long-term liabilities | ( | ( | |||||||||
Net cash and restricted cash provided by (used in) operating activities | ( | ||||||||||
Cash Flows Used In Investing Activities | |||||||||||
Cash paid for asset acquisitions and business combinations | ( | ( | |||||||||
Return of equity method investments | |||||||||||
Purchases of investments | ( | ||||||||||
Investments in internal-use software and purchases of property and equipment | ( | ( | |||||||||
Net cash and restricted cash used in investing activities | ( | ( | |||||||||
Cash Flows Provided by Financing Activities | |||||||||||
Changes in working capital balances related to claims processing | |||||||||||
Payment of contingent consideration | ( | ||||||||||
Proceeds from stock option exercises | |||||||||||
Proceeds from issuance of long-term debt, net of offering costs | ( | ||||||||||
Repayment of long-term debt | ( | ||||||||||
Proceeds from issuance of preferred stock, net of offering costs | |||||||||||
Payment of preferred dividends | ( | ( | |||||||||
Taxes withheld and paid for vesting of equity awards | ( | ( | |||||||||
Net cash and restricted cash provided by financing activities | |||||||||||
Effect of exchange rate on cash and cash equivalents and restricted cash | ( | ||||||||||
Net increase (decrease) in cash and cash equivalents and restricted cash | ( |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Cash and cash equivalents and restricted cash as of beginning-of-period | |||||||||||
Cash and cash equivalents and restricted cash as of end-of-period | $ | $ |
March 31, 2024 | December 31, 2023 | ||||||||||
Collateral for letters of credit for facility leases (1) | $ | $ | |||||||||
Collateral with financial institutions (2) | |||||||||||
Claims processing services (3) | |||||||||||
Total restricted cash and restricted investments | $ | $ | |||||||||
Current restricted cash | $ | ||||||||||
Total current restricted cash and restricted investments | $ | $ | |||||||||
Non-current restricted cash | $ | $ | |||||||||
Total non-current restricted cash and restricted investments | $ | $ |
March 31, | |||||||||||
2024 | 2023 | ||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Restricted cash and restricted investments | |||||||||||
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows | $ | $ |
Corporate trade name | |||||
Customer relationships | |||||
Technology | |||||
Provider network contracts |
Purchase consideration: | |||||
Cash | $ | ||||
Fair value of Class A common stock issued | |||||
Fair value of contingent consideration | |||||
Total consideration | $ | ||||
Tangible assets acquired: | |||||
Accounts receivable | $ | ||||
Prepaid expenses and other current assets | |||||
Total tangible assets acquired | |||||
Identifiable intangible assets acquired: | |||||
Customer relationships | |||||
Technology | |||||
Corporate trade name | |||||
Total identifiable intangible assets acquired | |||||
Liabilities assumed: | |||||
Accrued liabilities | |||||
Accrued compensation and employee benefits | |||||
Deferred tax liabilities, net | |||||
Deferred revenue | |||||
Total liabilities assumed | |||||
Goodwill (1) | |||||
Net assets acquired | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenue | $ | $ | |||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | ( |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Medicaid | $ | $ | |||||||||
Medicare | |||||||||||
Commercial and other | |||||||||||
Total | $ | $ | |||||||||
Performance Suite | $ | $ | |||||||||
Specialty Technology and Services Suite | |||||||||||
Administrative Services | |||||||||||
Cases | |||||||||||
Total | $ | $ |
March 31, 2024 | December 31, 2023 | ||||||||||
Short-term receivables (1) | $ | $ | |||||||||
Short-term deferred revenue | |||||||||||
Long-term deferred revenue |
Deferred revenue | |||||
Balance as of beginning-of-period | $ | ||||
Reclassification to revenue, as a result of performance obligations satisfied | ( | ||||
Cash received in advance of satisfaction of performance obligations | |||||
Balance as of end of period | $ |
March 31, 2024 | December 31, 2023 | ||||||||||
Current | % | % | |||||||||
Past due less than 60 days | % | % | |||||||||
Past due less than 120 days | % | % | |||||||||
Accounts receivable, net of allowance | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Balance as of beginning of period | $ | ( | $ | ( | |||||||
Acquisitions | ( | ||||||||||
Provision for credit losses | ( | ||||||||||
Charge-offs(1) | |||||||||||
Balance as of end of period | $ | ( | $ | ( |
March 31, 2024 | December 31, 2023 | ||||||||||
Computer hardware | $ | $ | |||||||||
Furniture and equipment | |||||||||||
Internal-use software development costs | |||||||||||
Leasehold improvements | |||||||||||
Total property and equipment | |||||||||||
Accumulated depreciation expense | ( | ( | |||||||||
Total property and equipment, net | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Balance, beginning of period | $ | $ | |||||||||
Goodwill acquired (1) | |||||||||||
Foreign currency translation | ( | ||||||||||
Balance, end of period | $ | $ |
March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||
Weighted- Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Net Carrying Value | Weighted- Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Net Carrying Value | ||||||||||||||||||||||||||||||||||||||||
Corporate trade name | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||
Customer relationships | |||||||||||||||||||||||||||||||||||||||||||||||
Technology | |||||||||||||||||||||||||||||||||||||||||||||||
Below market lease, net | |||||||||||||||||||||||||||||||||||||||||||||||
Provider network contracts | |||||||||||||||||||||||||||||||||||||||||||||||
Total intangible assets, net | $ | $ | $ | $ | $ | $ |
2024 | $ | ||||
2025 | |||||
2026 | |||||
2027 | |||||
2028 | |||||
Thereafter | |||||
Total future amortization of intangible assets | $ |
2025 Notes | 2029 Notes | ||||||||||
Aggregate principal amount at issuance | $ | $ | |||||||||
Interest rate per annum | % | % | |||||||||
Debt issuance costs | $ | $ | |||||||||
Net proceeds | $ | $ | |||||||||
Issuance date | October 22, 2018 | December 8, 2023 | |||||||||
Maturity date | October 15, 2025 | December 1, 2029 | |||||||||
Interest payment dates (1) | April 15 and October 15 | June 1 and December 1 | |||||||||
Conversion rate per $1,000 of principal | $ | 29.9135 | $ | 26.3125 | |||||||
Conversion price | $ | $ | |||||||||
Shares issuable upon conversion(2) | |||||||||||
Carrying value | $ | $ | |||||||||
Unamortized debt discount and issuance costs | |||||||||||
Outstanding principal | $ | $ | |||||||||
Remaining amortization period (years) | |||||||||||
Fair value (3) | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
2029 Notes | |||||||||||
Interest expense | $ | $ | — | ||||||||
Amortization of debt issuance costs | — | ||||||||||
Interest expense for 2029 Notes | $ | $ | — | ||||||||
2022 Credit Agreement | |||||||||||
Interest expense | $ | $ | |||||||||
Amortization of debt issuance costs | |||||||||||
Interest expense for 2022 Credit Agreement | $ | $ | |||||||||
2024 Notes | |||||||||||
Interest expense | $ | — | $ | ||||||||
Amortization of debt issuance costs | — | ||||||||||
Interest expense for 2024 Notes | $ | — | $ | ||||||||
2025 Notes | |||||||||||
Interest expense | $ | $ | |||||||||
Amortization of debt issuance costs | |||||||||||
Interest expense for 2025 Notes | $ | $ |
March 31, 2024 | December 31, 2023 | ||||||||||
Cook County Health and Hospitals System | |||||||||||
Center for Medicare & Medicaid Services | * | ||||||||||
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Humana Insurance Company | * | ||||||||||
Florida Blue Medicare, Inc. | |||||||||||
Cook County Health and Hospitals System | |||||||||||
Molina Healthcare, Inc. | |||||||||||
Location | Lease Termination Term (in years) | Future Minimum Lease Commitments | Letter of Credit Amount Required | |||||||||||||||||
Arlington, VA (1) | $ | $ | ||||||||||||||||||
Edison, NJ | ||||||||||||||||||||
Makati City, Philippines | ||||||||||||||||||||
Alpharetta, GA | ||||||||||||||||||||
Pune, India | ||||||||||||||||||||
Brea, CA |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Operating lease cost | $ | $ | |||||||||
Variable lease cost | |||||||||||
Total lease cost | $ | $ |
Operating lease expense | |||||
2024 | $ | ||||
2025 | |||||
2026 | |||||
2027 | |||||
2028 | |||||
Thereafter | |||||
Total lease payments | |||||
Less: | |||||
Interest | |||||
Present value of lease liabilities | $ |
March 31, 2024 | |||||
Weighted average discount rate | % | ||||
Weighted average remaining lease term |
For the Three Month Period Ended | Payment Date | Dividends Per Share | Total Amount Paid | ||||||||
March 31, 2024 | 3/28/2024 | $ | $ | ||||||||
March 31, 2023 | 3/28/2023 | ||||||||||
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Loss before preferred dividends and accretion of Series A Preferred Stock | $ | ( | $ | ( | |||||||
Dividends and accretion of Series A Preferred Stock | ( | ( | |||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | ( | $ | ( | |||||||
Weighted-average common shares outstanding - basic and diluted | |||||||||||
Loss per common share | |||||||||||
Basic and diluted | $ | ( | $ | ( | |||||||
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") | |||||||||||
Stock options | |||||||||||
Series A Preferred Stock | |||||||||||
Convertible senior notes | |||||||||||
Total |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Award Type | |||||||||||
Stock options | $ | $ | |||||||||
RSUs | |||||||||||
LSUs | |||||||||||
PSUs | |||||||||||
Total compensation expense by award type | $ | $ | |||||||||
Line Item | |||||||||||
Cost of revenue | $ | $ | |||||||||
Selling, general and administrative expenses | |||||||||||
Total compensation expense by financial statement line item | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
RSUs | |||||||||||
PSUs |
March 31, 2024 | |||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Liabilities | |||||||||||||||||||||||
Contingent consideration(1) | $ | $ | $ | $ | |||||||||||||||||||
Total fair value of liabilities measured on a recurring basis | $ | $ | $ | $ |
December 31, 2023 | |||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Liabilities | |||||||||||||||||||||||
Contingent consideration | $ | $ | $ | $ | |||||||||||||||||||
Total fair value of liabilities measured on a recurring basis | $ | $ | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Balance as of beginning of period | $ | $ | |||||||||
Additions | |||||||||||
Settlements | ( | ( | |||||||||
Balance as of end of period | $ | $ |
March 31, 2024 | |||||||||||||||||||||||
Fair | Valuation | Significant | Assumption or | ||||||||||||||||||||
Value | Technique | Unobservable Inputs | Input Ranges | ||||||||||||||||||||
Contingent consideration | $ | N/A | Contractual terms | $ | |||||||||||||||||||
December 31, 2023 | |||||||||||||||||||||||
Fair | Valuation | Significant | Assumption or | ||||||||||||||||||||
Value | Technique | Unobservable Inputs | Input Ranges | ||||||||||||||||||||
Contingent consideration | $ | N/A | Contractual terms | $ |
March 31, 2024 | December 31, 2023 | ||||||||||
Assets | |||||||||||
Accounts receivable, net | $ | $ | |||||||||
Liabilities | |||||||||||
Accounts payable | $ | $ | |||||||||
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenue | $ | $ | |||||||||
Expenses | |||||||||||
Cost of revenue | |||||||||||
Selling, general and administrative expenses |
For the Three Months Ended March 31, 2024 | Cumulative Amount Incurred Through March 31, 2024 | Total Amount Expected to be Incurred in the 2023 Repositioning Plan | |||||||||||||||
Severance and termination benefits | $ | $ | $ | ||||||||||||||
Dedicated employee costs | |||||||||||||||||
Professional services | |||||||||||||||||
Office space consolidation | $ | ||||||||||||||||
Total | $ | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Balance, beginning of period | $ | $ | |||||||||
Incurred health care costs: | |||||||||||
Current year to date period | |||||||||||
Prior year to date period | ( | ( | |||||||||
Total claims incurred | |||||||||||
Claims paid related to: | |||||||||||
Current year to date period | ( | ( | |||||||||
Prior year to date period | ( | ( | |||||||||
Total claims paid | ( | ( | |||||||||
Balance, end of period | $ | $ |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Supplemental Disclosure of Non-cash Investing and Financing Activities | |||||||||||
Accrued property and equipment purchases | $ | ( | $ | ||||||||
Class A common stock issued in connection with business combinations | |||||||||||
Accrued net working capital adjustment with business combinations | |||||||||||
Effects of Leases | |||||||||||
Operating cash flows from operating leases | ( | ||||||||||
Leased assets disposed of (obtained in) exchange for operating lease liabilities | ( | ( | |||||||||
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Humana Insurance Company | 21.6% | * | |||||||||
Florida Blue Medicare, Inc. | 12.7% | 11.9% | |||||||||
Cook County Health and Hospitals Systems | 11.4% | 17.2% | |||||||||
Molina Healthcare, Inc. | 11.2% | 13.2% | |||||||||
For the Three Months Ended March 31, 2024 | Cumulative Amount Incurred Through March 31, 2024 | Total Amount Expected to be Incurred in the 2023 Repositioning Plan | |||||||||||||||
Severance and termination benefits | $ | 1,804 | $ | 10,368 | $ | 12,368 | |||||||||||
Dedicated employee costs | 1,185 | 8,085 | 8,229 | ||||||||||||||
Professional services | 3,488 | 16,399 | 17,865 | ||||||||||||||
Office space consolidation | 3,452 | 10,314 | $ | 10,314 | |||||||||||||
Total | $ | 9,929 | $ | 45,166 | $ | 48,776 |
(in thousands, except percentages) | For the Three Months Ended March 31, | Change Over Prior Period | |||||||||||||||||||||
2024 | 2023 | $ | % | ||||||||||||||||||||
Revenue | $ | 639,653 | $ | 427,690 | $ | 211,963 | 49.6% | ||||||||||||||||
Expenses | |||||||||||||||||||||||
Cost of revenue | 535,547 | 310,475 | 225,072 | 72.5% | |||||||||||||||||||
Selling, general and administrative expenses | 79,104 | 89,726 | (10,622) | (11.8)% | |||||||||||||||||||
Depreciation and amortization expenses | 29,503 | 29,275 | 228 | 0.8% | |||||||||||||||||||
Change in fair value of contingent consideration | 8,908 | 8,569 | 339 | 4.0% | |||||||||||||||||||
Total operating expenses | 653,062 | 438,045 | 215,017 | 49.1% | |||||||||||||||||||
Operating loss | $ | (13,409) | $ | (10,355) | $ | (3,054) | (29.5)% | ||||||||||||||||
Cost of revenue as a % of revenue | 83.7 | % | 72.6 | % | |||||||||||||||||||
Selling, general and administrative expenses as a % of revenue | 12.4 | % | 21.0 | % |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Medicaid | $ | 215,124 | $ | 183,034 | |||||||
Medicare | 286,960 | 127,669 | |||||||||
Commercial and other | 137,569 | 116,987 | |||||||||
Total | $ | 639,653 | $ | 427,690 |
Average Lives on Platform/ Cases | Average PMPM Fees / Revenue per Case | ||||||||||||||||||||||
For the Three Months Ended March 31, | For the Three Months Ended March 31, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Performance Suite | 7,050 | 3,242 | $ | 21.19 | $ | 24.66 | |||||||||||||||||
Specialty Technology and Services Suite | 72,302 | 60,503 | 0.41 | 0.36 | |||||||||||||||||||
Administrative Services | 1,254 | 1,857 | 15.57 | 14.91 | |||||||||||||||||||
Cases | 15 | 15 | 2,849 | 2,555 | |||||||||||||||||||
Average Unique Members | 39,888 | 41,268 |
For the Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Net cash and restricted cash provided by (used in) operating activities | $ | 4,909 | $ | (7,974) | |||||||
Net cash and restricted cash used in investing activities | (9,732) | (394,993) | |||||||||
Net cash and restricted cash provided by financing activities | 14,882 | 379,729 |
2024 | 2025-2026 | 2027-2028 | 2029+ | Total | |||||||||||||||||||||||||
Operating leases for facilities | $ | 13,024 | $ | 15,904 | $ | 12,764 | $ | 12,427 | $ | 54,119 | |||||||||||||||||||
Purchase obligations related to vendor contracts | 12,723 | 18,095 | 935 | — | 31,753 | ||||||||||||||||||||||||
Convertible notes interest payments | 16,401 | 30,763 | 28,175 | 14,088 | 89,427 | ||||||||||||||||||||||||
Convertible notes principal repayment | — | 172,500 | — | 402,500 | 575,000 | ||||||||||||||||||||||||
Contingent consideration (1) | 88,753 | — | — | — | 88,753 | ||||||||||||||||||||||||
Total known contractual obligations | $ | 130,901 | $ | 237,262 | $ | 41,874 | $ | 429,015 | $ | 839,052 |
101.INS | XBRL Instance Document | |||||||
101.SCH | XBRL Taxonomy Extension Schema Document | |||||||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |||||||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |||||||
104 | The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL |
EVOLENT HEALTH, INC. | ||||||||
Registrant | ||||||||
By: | /s/ John Johnson | |||||||
Name: | John Johnson | |||||||
Title: | Chief Financial Officer | |||||||
By: | /s/ Aammaad Shams | |||||||
Name: | Aammaad Shams | |||||||
Title: | Chief Accounting Officer and Controller |
Tranche | Vesting Date | ||||
First Tranche | [.] | ||||
Second Tranche | [.] |
If to Company: | Evolent Health, Inc. 1812 N. Moore Street, Suite 1705 Arlington, VA 22209 Attention: General Counsel | ||||
If to you: | To your address as most recently supplied to the Company and set forth in the Company’s records |
Dated: | May 9, 2024 | /s/ Seth Blackley | |||||||||
Name: Seth Blackley | |||||||||||
Title: Chief Executive Officer |
Dated: | May 9, 2024 | /s/ John Johnson | |||||||||
Name: John Johnson | |||||||||||
Title: Chief Financial Officer |
Dated: | May 9, 2024 | /s/ Seth Blackley | |||||||||
Name: Seth Blackley | |||||||||||
Title: Chief Executive Officer |
Dated: | May 9, 2024 | /s/ John Johnson | |||||||||
Name: John Johnson | |||||||||||
Title: Chief Financial Officer |
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Mezzanine Equity | ||
Preferred class A common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred class A common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Preferred class A common stock, shares issued (in shares) | 175,000 | 175,000 |
Shareholders' Equity | ||
Class A common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Class A common stock, shares authorized (in shares) | 750,000,000 | 750,000,000 |
Class A common stock, shares issued (in shares) | 116,195,270 | 115,424,833 |
Treasury stock, shares issued (in shares) | 1,537,582 | 1,537,582 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Income Statement [Abstract] | ||||
Revenue | [1] | $ 639,653 | $ 427,690 | |
Expenses | ||||
Cost of revenue | [1] | 535,547 | 310,475 | |
Selling, general and administrative expenses | [1] | 79,104 | 89,726 | |
Depreciation and amortization expenses | 29,503 | 29,275 | ||
Change in fair value of contingent consideration | 8,908 | 8,569 | ||
Total operating expenses | 653,062 | 438,045 | ||
Operating loss | (13,409) | (10,355) | ||
Interest income | 2,550 | 1,060 | ||
Interest expense | (5,997) | (12,895) | ||
Gain from equity method investees | 306 | 423 | ||
Change in tax receivables agreement liability | (173) | (66,184) | ||
Other income (expense), net | 8 | (220) | ||
Loss before income taxes | (16,715) | (88,171) | ||
Provision for (benefit from) income taxes | 565 | (68,189) | ||
Loss before preferred dividends and accretion of Series A Preferred Stock | (17,280) | (19,982) | ||
Dividends and accretion of Series A Preferred Stock | (7,945) | (6,276) | ||
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic | (25,225) | (26,258) | ||
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted | $ (25,225) | $ (26,258) | ||
Basic and diluted | ||||
Basic (in dollars per share) | $ (0.22) | $ (0.24) | ||
Diluted (in dollars per share) | $ (0.22) | $ (0.24) | ||
Weighted-average common shares outstanding | ||||
Basic (in shares) | 114,141 | 107,783 | ||
Diluted (in shares) | 114,141 | 107,783 | ||
Comprehensive loss | ||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ (25,225) | $ (26,258) | ||
Other comprehensive loss, net of taxes, related to: | ||||
Foreign currency translation adjustment | (51) | 56 | ||
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | $ (25,276) | $ (26,202) | ||
|
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands |
Total |
Performance-Based Restricted Stock Units (PSUs) |
Class A Common Stock |
Class A Common Stock
Performance-Based Restricted Stock Units (PSUs)
|
Additional Paid-In Capital |
Additional Paid-In Capital
Performance-Based Restricted Stock Units (PSUs)
|
Accumulated Other Comprehensive Income (Loss) |
Retained Earnings (Accumulated Deficit) |
Treasury Stock |
---|---|---|---|---|---|---|---|---|---|
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2022 | 0 | ||||||||
Series A preferred stock , Beginning balance at Dec. 31, 2022 | $ 0 | ||||||||
Increase (Decrease) in Temporary Equity [Roll Forward] | |||||||||
Issuance of series A preferred stock, net of issuance costs (in shares) | 175,000 | ||||||||
Issuance of series A preferred stock, net of issuance costs | $ 168,000 | ||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ 2,625 | ||||||||
Series A preferred stock , Ending balance (in shares) at Mar. 31, 2023 | 175,000 | ||||||||
Series A preferred stock , Ending balance at Mar. 31, 2023 | $ 170,625 | ||||||||
Beginning balance (in shares) at Dec. 31, 2022 | 101,501,000 | ||||||||
Beginning balance at Dec. 31, 2022 | 859,417 | $ 1,015 | $ 1,486,857 | $ (1,178) | $ (606,154) | $ (21,123) | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Stock-based compensation expense | 10,710 | 10,710 | |||||||
Exercise of stock options (in shares) | 330,000 | ||||||||
Exercise of stock options | 1,581 | $ 3 | 1,578 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 434,000 | ||||||||
Restricted stock units vested, net of shares withheld for taxes | (8,632) | $ 4 | (8,636) | ||||||
Stock units vested, net of shares withheld for taxes (in shares) | 760,000 | 202,000 | |||||||
Stock units vested, net of shares withheld for taxes | 0 | $ (3,975) | $ 8 | $ 2 | (8) | $ (3,977) | |||
Shares issued for acquisition (in shares) | 8,475,000 | ||||||||
Shares issued for acquisition | 261,271 | $ 85 | 261,186 | ||||||
Class A common stock issued for payment of earn-outs (in shares) | 850,000 | ||||||||
Class A common stock issued for payment of earn-outs | 27,573 | $ 8 | 27,565 | ||||||
Foreign currency translation adjustment | 56 | 56 | |||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | (26,258) | (6,276) | (19,982) | ||||||
Ending balance (in shares) at Mar. 31, 2023 | 112,552,000 | ||||||||
Ending balance at Mar. 31, 2023 | $ 1,121,743 | $ 1,125 | 1,768,999 | (1,122) | (626,136) | (21,123) | |||
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023 | 175,000 | ||||||||
Series A preferred stock , Beginning balance at Dec. 31, 2023 | $ 178,427 | ||||||||
Increase (Decrease) in Temporary Equity [Roll Forward] | |||||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ 2,867 | ||||||||
Series A preferred stock , Ending balance (in shares) at Mar. 31, 2024 | 175,000 | ||||||||
Series A preferred stock , Ending balance at Mar. 31, 2024 | $ 181,294 | ||||||||
Beginning balance (in shares) at Dec. 31, 2023 | 115,424,833 | 115,425,000 | |||||||
Beginning balance at Dec. 31, 2023 | $ 1,067,701 | $ 1,154 | 1,808,121 | (1,257) | (719,194) | (21,123) | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Stock-based compensation expense | 18,786 | 18,786 | |||||||
Exercise of stock options (in shares) | 96,000 | ||||||||
Exercise of stock options | 1,059 | $ 1 | 1,058 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 469,000 | ||||||||
Restricted stock units vested, net of shares withheld for taxes | (9,770) | $ 5 | (9,775) | ||||||
Stock units vested, net of shares withheld for taxes (in shares) | 205,000 | ||||||||
Stock units vested, net of shares withheld for taxes | $ (4,564) | $ 2 | $ (4,566) | ||||||
Foreign currency translation adjustment | (51) | (51) | |||||||
Net loss attributable to common shareholders of Evolent Health, Inc. | $ (25,225) | (7,945) | (17,280) | ||||||
Ending balance (in shares) at Mar. 31, 2024 | 116,195,270 | 116,195,000 | |||||||
Ending balance at Mar. 31, 2024 | $ 1,047,936 | $ 1,162 | $ 1,805,679 | $ (1,308) | $ (736,474) | $ (21,123) |
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Cash Flows Provided by (Used In) Operating Activities | ||
Net loss before preferred dividends and accretion of Series A preferred stock | $ (17,280) | $ (19,982) |
Adjustments to reconcile net loss to net cash and restricted cash provided by (used in) operating activities: | ||
Change in fair value of contingent consideration | 8,908 | 8,569 |
Gain from equity method investees | (306) | (423) |
Depreciation and amortization expenses | 29,503 | 29,275 |
Stock-based compensation expense | 18,786 | 10,710 |
Deferred tax provision | 181 | (68,728) |
Amortization of contract cost assets | 1,205 | 2,290 |
Amortization of deferred financing costs | 882 | 911 |
Change in tax receivables agreement liability | 173 | 66,184 |
Right-of-use operating assets | 1,193 | 4,620 |
Other current operating cash outflows, net | 6 | (56) |
Changes in assets and liabilities, net of acquisitions: | ||
Accounts receivable, net and contract assets | 19,009 | 19,832 |
Prepaid expenses and other current and non-current assets | 7,166 | (13,758) |
Contract cost assets | (1,556) | (1,326) |
Accounts payable | (8,421) | (13,585) |
Accrued liabilities | 10,635 | 4,785 |
Operating lease liabilities | (2,582) | (4,250) |
Accrued compensation and employee benefits | (27,279) | (31,401) |
Deferred revenue | 160 | 1,169 |
Reserve for claims and performance-based arrangements | (35,409) | (2,533) |
Other long-term liabilities | (65) | (277) |
Net cash and restricted cash provided by (used in) operating activities | 4,909 | (7,974) |
Cash Flows Used In Investing Activities | ||
Cash paid for asset acquisitions and business combinations | (1,385) | (386,724) |
Return of equity method investments | 0 | 786 |
Purchases of investments | (3,000) | 0 |
Investments in internal-use software and purchases of property and equipment | (5,347) | (9,055) |
Net cash and restricted cash used in investing activities | (9,732) | (394,993) |
Cash Flows Provided by Financing Activities | ||
Changes in working capital balances related to claims processing | 37,520 | 7,576 |
Payment of contingent consideration | (3,755) | 0 |
Proceeds from stock option exercises | 1,058 | 1,581 |
Proceeds from issuance of long-term debt, net of offering costs | (529) | 256,330 |
Repayment of long-term debt | 0 | (37,500) |
Proceeds from issuance of preferred stock, net of offering costs | 0 | 168,000 |
Payment of preferred dividends | (5,078) | (3,651) |
Taxes withheld and paid for vesting of equity awards | (14,334) | (12,607) |
Net cash and restricted cash provided by financing activities | 14,882 | 379,729 |
Effect of exchange rate on cash and cash equivalents and restricted cash | (38) | 50 |
Net increase (decrease) in cash and cash equivalents and restricted cash | 10,021 | (23,188) |
Cash and cash equivalents and restricted cash as of beginning-of-period | 223,457 | 215,158 |
Cash and cash equivalents and restricted cash as of end-of-period | $ 233,478 | $ 191,970 |
Organization |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries is a market leader in connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. We work on behalf of health plans and other risk-bearing entities and payers (our customers) to support physicians and other healthcare providers (our users) in providing the best evidence-based care to their patients. We believe adherence to the best evidence supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall. As of March 31, 2024, the Company had unrestricted cash and cash equivalents of $165.1 million. The Company believes it has sufficient liquidity for at least the next twelve months as of the date the financial statements were available to be issued. The Company’s headquarters is located in Arlington, Virginia. Evolent Health LLC Governance Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC’s business and affairs and is responsible for the management of its business.
|
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles | Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2023 Form 10-K. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2023 Form 10-K for a complete summary of our significant accounting policies. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying unaudited interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets. Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:
———————— (1)Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2)Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement. (3)Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):
Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of its reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of its reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of our reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds our reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2023. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification:
As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we re-evaluated the useful lives of our intangible assets and accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets. Research and Development Costs Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss). Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 20 for additional discussion regarding our reserves for claims and performance-based arrangements. Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of March 31, 2024 and December 31, 2023, approximately 63% and 57%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March 31, 2024, approximately 22% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met. Additionally, the Company offsets its accounts receivable and claims reserve under its total cost of care management solution. Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. The Company reviews long-lived assets, which include operating lease right-of-use asset assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying values are reduced to the estimated fair value. Fair values are determined based on quoted market values, discounted cash flows and external market data, as applicable. The Company terminated a portion of its previous headquarters lease in Arlington, VA effective December 31, 2023 and recognized the impact of a $6.5 million termination penalty in its operating lease liability - current on its consolidated balance sheet. The termination payment consisted of two payments of $3.25 million, one payment was paid on October 1, 2023 and the other was paid on April 1, 2024. In addition, the Company terminated the remainder of its previous headquarters lease in Arlington, VA effective March 27, 2024 and recognized the impact of a $3.5 million termination penalty in its operating lease liability - current on its consolidated balance sheet. The termination payment of $3.5 million was paid on April 1, 2024. Refer to Note 11 for additional lease disclosures. Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care management and specialty care management services solutions, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation See Note 5 for further discussion of our policies related to revenue recognition. Series A Senior Convertible Preferred Shares In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company’s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares. Refer to Note 12 - Convertible Preferred Equity for further discussion.
|
Recently Issued Accounting Standards |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Recently Issued Accounting Standards | Recently Issued Accounting Standards Adoption of New Accounting Standards In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" ("ASU 2023-07"), which enhances the disclosures required for operating segments in the Company's annual and interim consolidated financial statements, including those companies with a single operating segment. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on our disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 includes requirements that an entity disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The standard also requires that entities disclose income (or loss) from continuing operations before income tax expense (or benefit) and income tax expense (or benefit) each disaggregated between domestic and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently assessing the impact of ASU 2023-09 on its disclosures.
|
Transactions |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transactions | Transactions Business Combinations National Imaging Associates Inc. On January 20, 2023, the Company completed its acquisition of NIA, including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (“Magellan”) and certain of its subsidiaries that were used in the Magellan Specialty Health division. NIA is a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. Total acquisition consideration, net of cash on hand and certain closing adjustments, was $715.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on January 20, 2023. The acquisition consideration consisted of approximately $387.8 million of cash consideration (inclusive of certain post-closing adjustments), 8.5 million shares of the Company’s Class A common stock, fair valued at $261.3 million as of January 20, 2023, and an earn-out consisting of additional consideration of up to $150.0 million payable in cash and, at the Company’s election, up to 50% in shares of the Company’s Class A common stock (the “Contingent Consideration”). As of January 20, 2023, the Contingent Consideration was fair valued at $66.6 million. See Note 17 for additional information regarding the fair value determination of the earn-out consideration. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):
(1)Goodwill acquired does not include $1.0 million of measurement period adjustments or of $2.4 million in reductions due to goodwill written off upon disposal of non-strategic assets subsequent to March 31, 2023. The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 15 years, 5 years, and 2 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of proprietary software that supports NIA’s core business applications and specialty business. The corporate trade name reflects the value that we believe the NIA brand name carries in the market, however due to organization changes we will retire the NIA trade name by December 2024. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a tax benefit of $56.1 million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets. Pro forma financial information (unaudited) The following unaudited condensed pro forma information presents combined financial information as if the acquisition of NIA had been effective as of January 1, 2022, the beginning of the 2022 fiscal year. The unaudited pro forma financial information includes adjustments to historical amounts including amortization of acquired intangible assets, depreciation of acquired property and equipment, interest expense for the financing of the transaction, alignment of NIA’s revenue recognition policy, and the associated income tax effects as if NIA had been included in the Company’s results of operations. This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands).
|
Revenue Recognition |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care management and specialty care management services solutions, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our partners and providers. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Our revenue includes certain services which are billed on a per-case basis. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the partner has requested both administrative services and other services such as our specialty care management or total cost of care management services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract-by-contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis. Disaggregation of Revenue The following table represents Evolent’s revenue disaggregated by end-market and product type (in thousands):
Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term greater than one year, we have allocated approximately $38.6 million of transaction price to performance obligations that are unsatisfied as of March 31, 2024. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 53% and 100% of these remaining performance obligations by December 31, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March 31, 2024 and December 31, 2023 (in thousands):
———————— (1)Excludes pharmacy rebate receivable and pharmacy claims receivable. Changes in deferred revenue for the three months ended March 31, 2024 are as follows (in thousands):
The amount of revenue, excluding customer discounts of $1.3 million, recognized from performance obligations satisfied (or partially satisfied) in a previous period was $18.0 million for the three months ended March 31, 2024 due primarily to net gain share as well as changes in other estimates. Contract Cost Assets Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March 31, 2024 and December 31, 2023, the Company had $3.1 million and $2.8 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $0.3 million for the three months ended March 31, 2024 and 2023, respectively. In our revenue contracts, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March 31, 2024 and December 31, 2023, the Company had $9.4 million and $9.3 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $0.9 million and $2.0 million for the three months ended March 31, 2024 and 2023, respectively. These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit is based on our technology, the nature of our partner arrangements and other factors.
|
Credit Losses |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Credit Loss [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Credit Losses | Credit Losses We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, current inflationary pressures on our customers’ and other third parties’ ability to pay, we did observe notable decreases in delinquencies with certain partners’ mainly due to timing of payments which resulted in a lower provision for credit losses of during the three months ended March 31, 2024. Accounts Receivable from Revenue Transactions Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company’s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company’s consolidated balance sheets. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts. The following table compiles the percentages of outstanding accounts receivable based on our aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets (in thousands):
The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):
———————— (1) Charge offs for the three months ended March 31, 2024 and 2023 are due primarily to balances written-off that were previously reserved.
|
Property and Equipment, Net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment, Net | Property and Equipment, Net The following summarizes our property and equipment (in thousands):
The Company capitalized $4.5 million and $8.1 million for the three months ended March 31, 2024 and 2023 respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $69.4 million and $70.9 million as of March 31, 2024 and December 31, 2023, respectively. Depreciation expense related to property and equipment was $7.5 million and $8.1 million for the three months ended March 31, 2024 and 2023 respectively, of which amortization expense related to capitalized internal-use software development costs was $6.3 million and $6.7 million for the three months ended March 31, 2024 ,and 2023 respectively.
|
Goodwill and Intangible Assets, Net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Our annual goodwill impairment review occurs on October 31 of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of our reporting unit may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended March 31, 2024. We will perform our annual impairment test of October 31, 2024. 2023 Goodwill Impairment Test On October 31, 2023, the Company performed its annual goodwill impairment review for fiscal year 2023. In addition, the Company underwent organizational changes which required a reassessment of reporting units. As a result, the Company determined it has one reporting unit due to the economic similarity of the services provided to our partners. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of our reporting unit was below its respective carrying values. As a result, a quantitative goodwill impairment analysis was not required. Change in Goodwill The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):
———————— (1)Goodwill acquired from the addition of NIA in January 2023 Intangible Assets, Net Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:
Amortization expense related to intangible assets was $22.0 million and $21.1 million for the three months ended March 31, 2024 and 2023, respectively. Future estimated amortization of intangible assets (in thousands) as of March 31, 2024, is as follows:
As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during the three months ended March 31, 2024, that would require an impairment test for our intangible assets.
|
Long-term Debt |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | Long-term Debt Terms of Convertible Senior Notes The Company issued $117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 in August 2020 (the “2024 Notes”) in privately negotiated exchange and/or subscription agreements, $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 in October 2018 (the “2025 Notes”) in private placements to qualified institutional buyers within the meaning of Rule 144A under the Securities Act and $402.5 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2029 in December 2023 (the “2029 Notes,” and together with the 2024 Notes and 2025 Notes, the “Convertible Senior Notes”), in private placements to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. All 2025 Notes and 2029 Notes will mature on the date in the table below, unless earlier repurchased, redeemed or converted in accordance with their respective terms prior to such date. As of October 13, 2023, no 2024 Notes remained outstanding. The Convertible Senior Notes are recorded on our accompanying consolidated balance sheets at their net carrying values. All of our Convertible Senior Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments and their fair values are Level 2 inputs. Refer to Note 17 for additional discussion on the fair value classifications of our Convertible Senior Notes. The 2025 Notes and 2029 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of Class A common stock per $1,000 principal amount of the 2025 Notes and 2029 Notes, which is equivalent to an initial conversion price of the Company’s Class A common stock. In the aggregate, the 2025 Notes and 2029 Notes are initially convertible into 20.3 million shares of the Company’s Class A common stock. The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The following table summarizes the terms of our Convertible Senior Notes as of March 31, 2024 (in thousands, except per share conversion rates and prices):
———————— (1)Holders of the Convertible Senior Notes are entitled to cash payments, which are payable semiannually in arrears on the dates indicated above. (2)Measured in shares of the Company’s Class A common stock and represents the number of shares of the Company’s Class A common stock that the Convertible Senior Notes are convertible into as of March 31, 2024. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. (3)Fair values for notes are derived from available trading prices closest to the respective balance sheet date. Holders of the 2025 Notes and 2029 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may redeem for cash all or any portion of the 2025 Notes, at its option if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert, at their option, all or any portion of their 2025 Notes at the conversion rate. The Company may not redeem the 2029 Notes prior to December 6, 2026. The Company may redeem for cash all or any portion of the 2029 Notes, at its option, on or after December 6, 2026, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Prior to the close of business on the business day immediately preceding September 1, 2029, the 2029 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions. At any time on or after September 1, 2029, until the close of business on the business day immediately preceding the maturity date, holders of the 2029 Notes may convert, at their option, all or any portion of their 2029 Notes at the conversion rate. 2024 Notes Exchange and Redemption On August 2, 2023, the Company issued a notice of redemption to the holders of its outstanding 2024 Notes, pursuant to which it redeemed the outstanding 2024 Notes for cash at a price of 100% of the principal amount of the 2024 Notes, plus accrued and unpaid interest, if any, on October 13, 2023 (the “Redemption Date”). Prior to the Redemption Date, holders of the 2024 Notes were entitled to convert to shares of the Company’s Class A Common Stock at a rate of 55.6153 shares per $1,000 principal amount of 2024 Notes. During the year ended December 31, 2023, holders of the 2024 Notes converted $23.3 million in aggregate principal amount of such notes to $1.3 million shares of the Company’s Class A common stock and the Company repaid the remaining $1.0 million balance in cash, satisfying all of the Company’s remaining payment obligations under the 2024 Notes on the Redemption Date. 2029 Notes Issuance In December 2023, the Company issued $402.5 million aggregate principal amount of its 2029 Notes in a private placement to qualified institutional buyers within the meaning of Rule 144A of the Securities Act. The 2029 Notes were issued at an issue price of 100.00% of par for net proceeds of approximately $390.9 million, after deducting fees and estimated expenses. We incurred $11.6 million of debt issuance costs in connection with the 2029 Notes. 2022 Credit Agreement On August 1, 2022 (the “IPG Closing Date”), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “ Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation (“Ares”), as administrative agent, collateral agent and revolver agent (the “Existing Credit Agreement” and as modified by the Amendment (defined below), the “Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) initial term loans in an aggregate principal amount of $175.0 million (the “Initial Term Loan Facility”) and (ii) revolving credit commitments in an aggregate principal amount of $50.0 million (the “Initial Revolving Facility”), the availability of which shall be determined by reference to the lesser of $50.0 million and a borrowing base calculation. The Borrowers borrowed full amount under the Initial Term Loan Facility and the Initial Revolving Facility on the IPG Closing Date. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Initial Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Initial Revolving Facility was paid as of the IPG Closing Date. On January 20, 2023, (“the NIA Closing Date”), the Company entered into Amendment No. 1 to the Credit Agreement (the “Amendment”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) additional revolving commitments in an aggregate principal amount equal to $25.0 million (the “Incremental Revolving Facility” and together with the Initial Revolving Facility, the Revolving Facility”), and (ii) additional term loans in an aggregate principal amount equal to $240.0 million, (the “Incremental Term Loan Facility” and together with the Initial Term Loan Facility, the “Term Loan Facility”; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the “Credit Facilities”). The Borrowers borrowed the full amount under the Incremental Term Loan Facility and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) 3.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 3.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. On December 5, 2023, the Company entered into Amendment No. 2 to the Credit Agreement pursuant to which the lenders agreed to certain mechanical changes necessary to permit issuance by the Company of additional unsecured convertible notes. The Credit Facilities are guaranteed by the Company and the Company’s domestic subsidiaries, subject to certain customary exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain customary exceptions. All loans under the Credit Facilities will mature on the date that is the earliest of (a) the sixth anniversary of the NIA Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied. The interest rate for the Loans is calculated, at the option of the Borrowers, (a) in the case of the Term Loan Facility, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of the Revolving Facility, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. Amounts outstanding under the Credit Facilities may be prepaid at the option of the Company, subject to the following prepayment premium (the “Prepayment Premium”) (subject to certain thresholds and carve outs): (1) 3.00% of the principal amount so prepaid after the NIA Closing Date but prior to the first anniversary of the NIA Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the NIA Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the NIA Closing Date but prior to the third anniversary of the NIA Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the NIA Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction, in each case, subject to application of the Prepayment Premium. The Prepayment Premium is also applicable upon any voluntary prepayment of the Term Loan Facility and any voluntary reduction or termination in the Revolving Facility. The Borrowers will pay an unused line fee equal to 0.50% times the result of (i) the aggregate amount of the Revolving Facility, less (ii) the average Revolving Facility usage during the immediately preceding month (or portion thereof), which fee shall be due and payable quarterly in arrears, on the first day of each calendar quarter from and after the IPG Closing Date and on the date on which (X) the Credit Facilities are paid in full in cash and (y) the Revolving Facility is otherwise terminated in accordance with the terms of the Credit Agreement. The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Loans. We incurred $14.6 million of debt issuance costs in connection with the Loans, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the Credit Agreement. During the year ended December 31, 2023, the Company prepaid $37.5 million under the Revolving Facility and $415.0 million of the Term Loan Facility that was utilized to acquire IPG and NIA. The total amount paid to Ares under the Credit Agreement in connection with the prepayment was $434.8 million, which included $415.0 million of principal, $9.1 million in accrued interest and $10.7 million in prepayment premium. As of March 31, 2024, there is $37.5 million outstanding under the Company’s Revolving Facility. Interest Expense Interest expense and amortization of debt issuance costs activity were as follows (in thousands):
|
Commitments and Contingencies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies | Commitments and Contingencies Commitments Letters of Credit As of March 31, 2024 and December 31, 2023, the Company was party to irrevocable standby letters of credit with a bank for $18.0 million and $17.9 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $18.6 million and $18.4 million, respectively, in restricted cash and restricted investments as collateral as of March 31, 2024 and December 31, 2023, respectively, inclusive of accrued interest. The letters of credit have current expiration dates between November 2024 and December 2025 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements. Guarantees On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina APA”), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the UHC’s Kentucky Medicaid Contract (the “Passport Medicaid Contract”). On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (“KY DOI”) regarding the wind down of its operations throughout 2021, 2022 and a portion of 2023. The wind down process is now complete and on October 10, 2023, the KY DOI approved our application to surrender our certificate of authority. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March 31, 2024, no amounts have been funded under this guarantee. UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. The Company recognized a TRA liability of $108.1 million and $107.9 million as of March 31, 2024 and December 31, 2023, respectively, which represents the Company’s estimate of the aggregate amount that it will pay under the TRA. During the three months ended March 31, 2024, we recorded an immaterial increase in the TRA liability. We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The total amount of the TRA liability may vary due to changes in federal and state income tax rates and availability of net operating losses. Contingencies Litigation Matters We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company’s Board was negligent in its oversight of the Company’s relationship with University Healthcare, Inc d/b/a Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D’Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (“Derivative Action”). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. On April 6, 2023, a shareholder of the Company sent a letter to the Company’s Board (the “Demand”) requesting that the Company’s Board of Directors (the “Board”), among other things, investigate alleged wrongdoing and commence litigation for breach of fiduciary duty against the individuals named as defendants in the Derivative Action. The Board considers it appropriate to investigate, evaluate, and consider the issues and matters raised in the Demand, and are working with outside counsel to do so. On February 15, 2024, the Board, following careful deliberation, responded that it was in the best interests of the Company and its stockholders to refuse to take the actions, including commencing litigation, that were made in the Demand. The Company cannot currently estimate the loss or the range of possible losses it may experience in connection with this request. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March 31, 2024, approximately 98.6% of our $233.5 million of cash and cash equivalents, restricted cash and restricted investments were held in either bank deposits with FDIC participating banks or overnight sweep accounts invested in money-market funds and approximately 1.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company has not experienced any realized losses on cash and cash equivalents to date; however, no assurances can be provided. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:
———————— * Represents less than 10.0% of the respective balance. In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our partners. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:
———————— * Represents less than 10.0% of the respective balance We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.
|
Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record such items in right-of-use assets and operating lease liabilities on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. Effective January 1, 2024, the Company’s primary office location is in Arlington, Virginia with a lease that expires in December 2030. In connection with various lease agreements, the Company is required to maintain $2.2 million and $2.1 million in letters of credit as of March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024 and December 31, 2023, the Company held $2.2 million and $2.1 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively. The Company terminated a portion of its previous headquarters lease in Arlington, VA effective December 31, 2023 and recognized the impact of a $6.5 million termination penalty in its operating lease liability - current on its consolidated balance sheet. The termination payment consisted of two payments of $3.25 million that were paid on October 1, 2023 and April 1, 2024. In addition, the Company terminated the remainder of its previous headquarters lease in Arlington, VA effective March 27, 2024 and recognized the impact of a $3.5 million termination penalty in its operating lease liability - current on its consolidated balance sheet. The termination payment of $3.5 million was paid on April 1, 2024. The following table summarizes our primary office leases as of March 31, 2024 (in thousands, other than term):
———————— (1) Amounts required under the letter of credit for our previous headquarters’ lease in Arlington, VA until December 2024. The following table summarizes the components of our lease expense (in thousands):
Maturity of lease liabilities (in thousands) is as follows:
Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:
|
Convertible Preferred Equity |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||
Temporary Equity Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Preferred Equity | Convertible Preferred Equity In connection with the NIA closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the “Securities Purchase Agreement”) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Series A Preferred Stock, par value $0.01 (the “Series A Preferred Stock”), at a purchase price of $960.00 per share, resulting in total gross proceeds to the Company of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Incremental Revolving Facility and Incremental Term Loan Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company’s Class A common stock, par value $0.01 per share and all future series of the Company’s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000.00 per share. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designation of the of the Series A Preferred Stock filed by the Company with the Delaware Secretary of State on January 19, 2023 (the “Certificate of Designation”)) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company’s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments. Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designation. The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025. If the Company undergoes a Change of Control (as defined in the Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control. In connection with the NIA closing, the Company entered into an Investors Rights Agreement with the Purchasers named in Schedule I thereto (the “Investors Rights Agreement”). The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Investors Rights Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement. In connection with the NIA closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders named in Schedule I thereto, which granted certain registration rights to Ares in respect of the shares of the Company’s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. The Company accreted $2.9 million of deferred issuance costs and redemption value in excess of par value in additional paid-in- capital on the consolidated balance sheets for the three months ended March 31, 2024. The Company paid dividends related to the Series A Preferred Stock as presented below during the three months ended March 31, 2024:
|
Loss Per Common Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss Per Common Share | Loss Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):
Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method). Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):
|
Stock-based Compensation |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based Compensation | Stock-based Compensation Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):
No stock-based compensation was capitalized as software development costs during the three months ended March 31, 2024 and 2023, respectively. Stock-based awards were granted as follows (in thousands):
|
Income Taxes |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes We have historically calculated the provision (benefit) for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full year to ordinary income or loss (pretax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. We have used a discrete effective tax rate method to calculate taxes for the three months ended March 31, 2024. We determined that since small changes in estimated ordinary income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three months ended March 31, 2024. An income tax provision (benefit) of $0.6 million and $(68.2) million was recognized for the three months ended March 31, 2024 and 2023 respectively, which resulted in effective tax rates of (3.4)% and 77.3%, respectively. The income tax expense recorded during the three months ended March 31, 2024 primarily relates to state and foreign taxes. The income tax benefit recorded during the three months ended March 31, 2023, primarily relates to the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the NIA acquisition accounting, partially offset by state and foreign taxes. As of March 31, 2024, the Company had unrecognized tax benefits of $2.7 million that, if recognized, would affect the overall effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above for discussion of our TRA.
|
Investments and Equity Method Investees |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Investments and Equity Method Investees | Investments and Equity Method Investees The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. Our joint ventures may include put or call features under which we could be forced to extend purchase or buy interests from our joint venture partner. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs. As of March 31, 2024 and December 31, 2023, the Company’s economic interests in its equity method investments ranged between 4% and 34%, and voting interests in its equity method investments ranged between 25% and 34%. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the gain from these investments was approximately $0.3 million and $0.4 million for the three months ended March 31, 2024 and 2023, respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $3.8 million and $4.8 million for the three months ended March 31, 2024 and 2023, respectively. Investments During the quarter ended March 31, 2024, the Company entered into an agreement to invest $3.0 million in future equity notes. Investment in future equity notes without readily determinable fair values are accounted for as cost method investments. The Company has elected to apply the measurement alternative to measure the investment at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. For the three months ended March 31, 2024, the Company did not record any unrealized gains or losses resulting from observable price changes of future equity notes without readily determinable fair values. As of March 31, 2024, the carrying amount of the investment was $3.0 million.
|
Fair Value Measurement |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurement | Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: •Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; •Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and •Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands):
———————— (1) Represents the earn-out consideration related to the NIA transaction as described in Note 4 and was paid in cash in April 2024. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2024. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. The acquisition of NIA includes a provision for additional equity consideration, at the Company’s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the NIA contingent consideration is the year ending December 31, 2023 and the earnout was paid in cash during the second quarter of 2024. The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands):
The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:
Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 9 for information regarding the fair value of the 2025 and 2029 Notes.
|
Related Parties |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Transactions [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Parties | Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements. The Company had an economic relationship through the ordinary course of business with an entity whose President and Chief Executive Officer was a member of our Board until his retirement from the Board in February 2024, that accounted for the majority of our related party revenue and cost of revenue for the three months ended March 31, 2024 and 2023, respectively. As discussed in Note 16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. The following table presents assets and liabilities attributable to our related parties (in thousands):
The following table presents revenues and expenses attributable to our related parties (in thousands):
|
Repositioning and Other Changes |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repositioning and Other Changes | Repositioning and Other Changes We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. During the second quarter of 2023, the Company implemented a broad set of repositioning initiatives designed to further align the Company’s assets and talent towards the value-based specialty care opportunity, with the intent of streamlining its operations and supporting the goal of realizing long-term sustainable earnings growth (the “2023 Repositioning Plan’). These initiatives include making organizational changes across the business that resulted in severance, terminated benefits and related payroll taxes and dedicated employee costs associated with recent acquisitions as well as third-party professional fees. Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent’s integrated technology platform and costs related to the consolidation of brands, internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed. Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods. Office space consolidation includes early termination penalties and associated expenses. As of March 31, 2024, the Company estimates total repositioning charges of $48.8 million to be incurred during the life of “the 2023 Repositioning Plan” which will be recorded in selling, general and administrative expenses on the consolidated statements of operations and comprehensive income (loss). The repositioning program is anticipated to be substantially complete by the end of the second quarter of 2024. The following table provides a summary of our total costs associated with our repositioning plans for the three months ended March 31, 2024, by major type of cost (in thousands):
|
Reserves for Claims and Performance-Based Arrangements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insurance [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserves for Claims and Performance-Based Arrangements | Reserve for Claims and Performance-Based Arrangements The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its specialty care management services solutions. Reserves for claims and performance-based arrangements reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its specialty care management services is calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy for reserves related to its specialty care management services solutions is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. Activity in reserves for claims and performance-based arrangements related to specialty care management services solution was as follows (in thousands):
|
Supplemental Cash Flow Information |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Information | Supplemental Cash Flow Information The following represents supplemental cash flow information (in thousands):
|
Pay vs Performance Disclosure - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Pay vs Performance Disclosure | ||
Loss before preferred dividends and accretion of Series A Preferred Stock | $ (17,280) | $ (19,982) |
Insider Trading Arrangements |
3 Months Ended |
---|---|
Mar. 31, 2024
shares
| |
Trading Arrangements, by Individual | |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Seth Blackley [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On February 29, 2024, Seth Blackley, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Blackley Plan”). The first possible trade date under the Blackley Plan is June 17, 2024 and the end date of the Blackley Plan is December 2, 2024. The aggregate amount of securities that may be sold under the Blackley Plan is 238,462 shares.
|
Name | Seth Blackley |
Title | Chief Executive Officer and a member of the Company’s Board of Directors |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | February 29, 2024 |
Arrangement Duration | 168 days |
Aggregate Available | 238,462 |
John Johnson [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On March 1, 2024, John Johnson, the Company’s Chief Financial Officer, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Johnson Plan”). The first possible trade date under the Johnson Plan is June 10, 2024 and the end date of the Johnson Plan is January 31, 2025. The aggregate amount of securities that may be sold under the Johnson Plan is 54,693 shares. |
Name | John Johnson |
Title | Chief Financial Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | March 1, 2024 |
Arrangement Duration | 235 days |
Aggregate Available | 54,693 |
Daniel McCarthy [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On March 1, 2024, Daniel McCarthy, the Company’s President, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Securities Exchange Act of 1934 (the “McCarthy Plan”). The first possible trade date under the McCarthy Plan is May 31, 2024 and the end date of the McCarthy Plan is February 20, 2025. The aggregate amount of securities that may be sold under the McCarthy Plan is 61,388 shares |
Name | Daniel McCarthy |
Title | President |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | March 1, 2024 |
Arrangement Duration | 265 days |
Aggregate Available | 61,388 |
Emily Rafferty [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On March 8, 2024, Emily Rafferty, the Company’s Chief Operating Officer, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Rafferty Plan”). The first possible trade date under the Rafferty Plan is June 17, 2024 and the end date of the Rafferty Plan is December 31, 2024. The aggregate amount of securities that may be sold under the Rafferty Plan is 8,861 shares. |
Name | Emily Rafferty |
Title | Chief Operating Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | March 8, 2024 |
Arrangement Duration | 197 days |
Aggregate Available | 8,861 |
Jonathan Weinberg [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | On February 28, 2024, Jonathan Weinberg, the Company’s General Counsel, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Weinberg Plan”). The first possible trade date under the Weinberg Plan is May 29, 2024 and the end date of the Weinberg Plan is January 31, 2025. The aggregate amount of securities that may be sold under the Weinberg Plan is 58,395 shares. |
Name | Jonathan Weinberg |
Title | General Counsel |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | February 28, 2024 |
Arrangement Duration | 247 days |
Aggregate Available | 58,395 |
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Presentation | Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2023 Form 10-K.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Estimates and Assumptions | Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying unaudited interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principles of Consolidation | Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents | Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Restricted Investments | Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:
———————— (1)Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2)Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement. (3)Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations | Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill | Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of its reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of its reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of our reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds our reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets, Net | Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification:
As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we re-evaluated the useful lives of our intangible assets and accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and Development Costs | Research and Development Costs Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserves for Claims and Performance-based Arrangements | Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Right of Offset | Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of March 31, 2024 and December 31, 2023, approximately 63% and 57%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March 31, 2024, approximately 22% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met. Additionally, the Company offsets its accounts receivable and claims reserve under its total cost of care management solution.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. The Company reviews long-lived assets, which include operating lease right-of-use asset assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying values are reduced to the estimated fair value. Fair values are determined based on quoted market values, discounted cash flows and external market data, as applicable.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care management and specialty care management services solutions, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation See Note 5 for further discussion of our policies related to revenue recognition. Series A Senior Convertible Preferred Shares In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company’s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares. Refer to Note 12 - Convertible Preferred Equity for further discussion. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our partners and providers. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Our revenue includes certain services which are billed on a per-case basis. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the partner has requested both administrative services and other services such as our specialty care management or total cost of care management services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract-by-contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adoption of New Accounting Standards | Adoption of New Accounting Standards In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" ("ASU 2023-07"), which enhances the disclosures required for operating segments in the Company's annual and interim consolidated financial statements, including those companies with a single operating segment. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on our disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 includes requirements that an entity disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The standard also requires that entities disclose income (or loss) from continuing operations before income tax expense (or benefit) and income tax expense (or benefit) each disaggregated between domestic and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently assessing the impact of ASU 2023-09 on its disclosures.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurement | Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: •Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; •Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and •Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.
|
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restricted Cash and Restricted Investments | Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:
———————— (1)Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2)Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement. (3)Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Consolidated Statements of Cash Flows | The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Estimated Useful Lives Assets | The following summarizes the estimated useful lives by asset classification:
Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:
|
Transactions (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Allocation of Purchase Price | The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assets Acquired and Liabilities | The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Pro Forma Adjustments | This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands).
|
Revenue Recognition (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Disaggregation of Revenue | The following table represents Evolent’s revenue disaggregated by end-market and product type (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Contract with Customer, Asset and Liability | The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March 31, 2024 and December 31, 2023 (in thousands):
———————— (1)Excludes pharmacy rebate receivable and pharmacy claims receivable. Changes in deferred revenue for the three months ended March 31, 2024 are as follows (in thousands):
|
Credit Losses (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Credit Loss [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accounts Receivable Aging Analysis | The following table compiles the percentages of outstanding accounts receivable based on our aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Changes in Allowance for Accounts Receivable | The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):
———————— (1) Charge offs for the three months ended March 31, 2024 and 2023 are due primarily to balances written-off that were previously reserved.
|
Property and Equipment, Net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Property and Equipment | The following summarizes our property and equipment (in thousands):
|
Goodwill and Intangible Assets, Net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Change in Goodwill | The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):
———————— (1)Goodwill acquired from the addition of NIA in January 2023
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Intangible Assets, Net | The following summarizes the estimated useful lives by asset classification:
Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Estimated Amortization of Intangible Assets | Future estimated amortization of intangible assets (in thousands) as of March 31, 2024, is as follows:
|
Long-term Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Convertible Debt | The following table summarizes the terms of our Convertible Senior Notes as of March 31, 2024 (in thousands, except per share conversion rates and prices):
———————— (1)Holders of the Convertible Senior Notes are entitled to cash payments, which are payable semiannually in arrears on the dates indicated above. (2)Measured in shares of the Company’s Class A common stock and represents the number of shares of the Company’s Class A common stock that the Convertible Senior Notes are convertible into as of March 31, 2024. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. (3)Fair values for notes are derived from available trading prices closest to the respective balance sheet date.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Debt | Interest expense and amortization of debt issuance costs activity were as follows (in thousands):
|
Commitments and Contingencies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Credit and Concentration Risk | The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:
———————— * Represents less than 10.0% of the respective balance. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:
———————— * Represents less than 10.0% of the respective balance
|
Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Primary Office Leases and Maturity of Lease Liabilities | The following table summarizes our primary office leases as of March 31, 2024 (in thousands, other than term):
———————— (1) Amounts required under the letter of credit for our previous headquarters’ lease in Arlington, VA until December 2024. Maturity of lease liabilities (in thousands) is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms | The following table summarizes the components of our lease expense (in thousands):
Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:
|
Convertible Preferred Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||
Temporary Equity Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Paid Dividends | The Company paid dividends related to the Series A Preferred Stock as presented below during the three months ended March 31, 2024:
|
Loss Per Common Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Computation of Basic and Diluted Earnings Per Share | The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share | Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):
|
Stock-based Compensation (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock-Based Compensation Expense | Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock-Based Awards Granted | Stock-based awards were granted as follows (in thousands):
|
Fair Value Measurement (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assets and Liabilities on Recurring Basis | The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands):
———————— (1) Represents the earn-out consideration related to the NIA transaction as described in Note 4 and was paid in cash in April 2024.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Changes in Contingent Consideration Measured at Fair Value | The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Valuation Techniques and Significant Unobservable Inputs | The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:
|
Related Parties (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Transactions [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Related Parties | The following table presents assets and liabilities attributable to our related parties (in thousands):
The following table presents revenues and expenses attributable to our related parties (in thousands):
|
Repositioning and Other Changes (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Costs Associated with the Repositioning Plan | The following table provides a summary of our total costs associated with our repositioning plans for the three months ended March 31, 2024, by major type of cost (in thousands):
|
Reserves for Claims and Performance-Based Arrangements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insurance [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Activity in Claims Reserves and Performance - Based Arrangements | Activity in reserves for claims and performance-based arrangements related to specialty care management services solution was as follows (in thousands):
|
Supplemental Cash Flow Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Supplemental Cash Flow Information | The following represents supplemental cash flow information (in thousands):
|
Organization (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
Mar. 31, 2023 |
---|---|---|---|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Cash and cash equivalents | $ 165,147 | $ 192,825 | $ 157,519 |
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Schedule of Restricted Cash and Restricted Investments (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
Mar. 31, 2023 |
---|---|---|---|
Restricted Cash and Cash Equivalents Items [Line Items] | |||
Total restricted cash and restricted investments | $ 68,331 | $ 30,632 | $ 34,451 |
Current restricted cash | 51,594 | 13,768 | |
Total current restricted cash and restricted investments | 51,594 | 13,768 | |
Non-current restricted cash | 16,737 | 16,864 | |
Total non-current restricted cash and restricted investments | 16,737 | 16,864 | |
Collateral for letters of credit for facility leases | |||
Restricted Cash and Cash Equivalents Items [Line Items] | |||
Total restricted cash and restricted investments | 2,219 | 2,132 | |
Collateral with financial institutions | |||
Restricted Cash and Cash Equivalents Items [Line Items] | |||
Total restricted cash and restricted investments | 16,331 | 16,237 | |
Claims processing services | |||
Restricted Cash and Cash Equivalents Items [Line Items] | |||
Total restricted cash and restricted investments | $ 49,781 | $ 12,263 |
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Schedule of Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|---|---|
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 165,147 | $ 192,825 | $ 157,519 | |
Restricted cash and restricted investments | 68,331 | 30,632 | 34,451 | |
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows | $ 233,478 | $ 223,457 | $ 191,970 | $ 215,158 |
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Narrative (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 27, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
option
payment
|
Dec. 31, 2023
USD ($)
payment
|
|
Accounting Policies [Abstract] | |||
Accounts receivable netted against claims payable | 63.00% | 57.00% | |
Accounts receivable, net eligible for net basis settlement | 22.00% | ||
Number of leases option | option | 1 | ||
Loss on termination of lease | $ 3,500 | $ 6,500 | |
Number of lease termination payment | payment | 2 | 2 | |
Termination payment paid | $ 3,500 | $ 3,250 | $ 3,250 |
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Schedule of Estimated Useful Lives Assets (Details) |
Mar. 31, 2024 |
---|---|
Corporate trade name | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 1 year |
Customer relationships | Minimum | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 11 years |
Customer relationships | Maximum | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 25 years |
Technology | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 5 years |
Provider network contracts | Minimum | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 3 years |
Provider network contracts | Maximum | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 5 years |
Transactions - Narrative (Details) - USD ($) shares in Millions |
3 Months Ended | 12 Months Ended | ||
---|---|---|---|---|
Jan. 20, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Business Acquisition [Line Items] | ||||
Cash | $ 1,385,000 | $ 386,724,000 | ||
Discrete tax benefit | $ (565,000) | $ 68,189,000 | ||
Corporate trade name | ||||
Business Acquisition [Line Items] | ||||
Finite-lived intangible asset, useful life | 1 year | |||
NIA | ||||
Business Acquisition [Line Items] | ||||
Total consideration | $ 715,694,000 | |||
Cash | 387,823,000 | |||
Fair value of Class A common stock issued | 261,271,000 | |||
Contingent consideration arrangements (up to) | $ 150,000,000 | |||
Percentage of contingent consideration allowed to be paid in equity interest (up to) | 50.00% | |||
Contingent consideration | $ 66,600,000 | |||
Goodwill, expected tax deductible amount | $ 0 | |||
Discrete tax benefit | $ 56,100,000 | |||
NIA | Customer relationships | ||||
Business Acquisition [Line Items] | ||||
Finite-lived intangible asset, useful life | 15 years | |||
NIA | Technology | ||||
Business Acquisition [Line Items] | ||||
Finite-lived intangible asset, useful life | 5 years | |||
NIA | Corporate trade name | ||||
Business Acquisition [Line Items] | ||||
Finite-lived intangible asset, useful life | 2 years | |||
NIA | Common Class A | ||||
Business Acquisition [Line Items] | ||||
Equity interest issued or issuable, number of shares (in shares) | 8.5 |
Transactions - Schedule of Allocation of Purchase Price and Net Assets Acquired (Details) - USD ($) $ in Thousands |
3 Months Ended | 14 Months Ended | ||||
---|---|---|---|---|---|---|
Jan. 20, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
Purchase consideration: | ||||||
Cash | $ 1,385 | $ 386,724 | ||||
Liabilities assumed: | ||||||
Goodwill | 1,116,539 | $ 1,117,945 | $ 1,116,539 | $ 1,116,542 | $ 722,774 | |
Goodwill disposal | $ 2,400 | |||||
NIA | ||||||
Purchase consideration: | ||||||
Cash | $ 387,823 | |||||
Fair value of Class A common stock issued | 261,271 | |||||
Fair value of contingent consideration | 66,600 | |||||
Total consideration | 715,694 | |||||
Tangible assets acquired: | ||||||
Accounts receivable | 28,065 | |||||
Prepaid expenses and other current assets | 675 | |||||
Total tangible assets acquired | 28,740 | |||||
Identifiable intangible assets acquired: | ||||||
Total identifiable intangible assets acquired | 404,000 | |||||
Liabilities assumed: | ||||||
Accrued liabilities | 5,409 | |||||
Accrued compensation and employee benefits | 6,173 | |||||
Deferred tax liabilities, net | 100,486 | |||||
Deferred revenue | 142 | |||||
Total liabilities assumed | 112,210 | |||||
Goodwill | 395,164 | |||||
Net assets acquired | 715,694 | |||||
Goodwill, purchase accounting adjustments | $ 1,000 | |||||
NIA | Customer relationships | ||||||
Identifiable intangible assets acquired: | ||||||
Total identifiable intangible assets acquired | 345,100 | |||||
NIA | Technology | ||||||
Identifiable intangible assets acquired: | ||||||
Total identifiable intangible assets acquired | 50,700 | |||||
NIA | Corporate trade name | ||||||
Identifiable intangible assets acquired: | ||||||
Total identifiable intangible assets acquired | $ 8,200 |
Transactions - Schedule of Pro Forma Adjustments (Details) - NIA - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Business Acquisition [Line Items] | ||
Revenue | $ 0 | $ 446,740 |
Net loss attributable to common shareholders of Evolent Health, Inc. | $ 0 | $ (15,730) |
Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Disaggregation of Revenue [Line Items] | ||||
Revenue | [1] | $ 639,653 | $ 427,690 | |
Evolent Health Services Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 639,653 | 427,690 | ||
Evolent Health Services Segment | Performance Suite | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 448,218 | 239,873 | ||
Evolent Health Services Segment | Specialty Technology and Services Suite | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 89,003 | 65,316 | ||
Evolent Health Services Segment | Administrative Services | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 58,569 | 83,067 | ||
Evolent Health Services Segment | Cases | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 43,863 | 39,434 | ||
Evolent Health Services Segment | Medicaid | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 215,124 | 183,034 | ||
Evolent Health Services Segment | Medicare | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 286,960 | 127,669 | ||
Evolent Health Services Segment | Commercial and other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 137,569 | $ 116,987 | ||
|
Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions |
Mar. 31, 2024
USD ($)
|
---|---|
Revenue from Contract with Customer [Abstract] | |
Performance obligation | $ 38.6 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | December 31, 2024 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percentage | 53.00% |
Remaining performance obligation, expected timing of satisfaction, period | 9 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | December 31, 2025 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percentage | 100.00% |
Remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue Recognition - Schedule of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
|
Revenue from Contract with Customer [Abstract] | ||
Short-term receivables | $ 426,561 | $ 446,220 |
Short-term deferred revenue | 6,136 | 5,976 |
Long-term deferred revenue | 879 | $ 1,173 |
Deferred revenue | ||
Balance as of beginning-of-period | 7,149 | |
Reclassification to revenue, as a result of performance obligations satisfied | (3,277) | |
Cash received in advance of satisfaction of performance obligations | 3,143 | |
Balance as of end of period | 7,015 | |
Revenue | 1,300 | |
Revenue recognized from performed obligations | $ 18,000 |
Revenue Recognition - Contract Costs Assets (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Capitalized Contract Cost [Line Items] | |||
Contract cost amortization | $ 1,205 | $ 2,290 | |
Amortization period | 5 years | ||
Bonuses and Commissions | |||
Capitalized Contract Cost [Line Items] | |||
Contract cost assets | $ 3,100 | $ 2,800 | |
Contract cost amortization | 300 | 300 | |
Contract Fulfillment Costs | |||
Capitalized Contract Cost [Line Items] | |||
Contract cost assets | 9,400 | $ 9,300 | |
Contract cost amortization | $ 900 | $ 2,000 |
Credit Losses - Accounts Receivable, Current, Past and Current Due (Details) - USD ($) $ in Millions |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Accounts Receivable, Noncurrent, Past Due [Line Items] | ||
Percentage of receivables, current | 58.00% | 54.00% |
Accounts receivable, net | $ 430 | $ 472 |
Past due less than 60 days | ||
Accounts Receivable, Noncurrent, Past Due [Line Items] | ||
Percentage of receivables, past due | 16.00% | 17.00% |
Past due less than 120 days | ||
Accounts Receivable, Noncurrent, Past Due [Line Items] | ||
Percentage of receivables, past due | 26.00% | 26.00% |
Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | ||
Balance as of beginning of period | $ (16,361) | $ (10,180) |
Acquisitions | 0 | (240) |
Provision for credit losses | 2,397 | (5,482) |
Charge-offs | 2,133 | 829 |
Balance as of end of period | $ (11,831) | $ (15,073) |
Property and Equipment, Net (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Property and Equipment [Line Items] | |||
Total property and equipment | $ 234,278 | $ 236,763 | |
Accumulated depreciation expense | (158,234) | (158,569) | |
Total property and equipment, net | 76,044 | 78,194 | |
Net capitalized internal-use software development costs | 69,400 | 70,900 | |
Depreciation expense | 7,500 | $ 8,100 | |
Capitalized computer software, amortization | 6,300 | 6,700 | |
Computer hardware | |||
Property and Equipment [Line Items] | |||
Total property and equipment | 14,055 | 21,501 | |
Furniture and equipment | |||
Property and Equipment [Line Items] | |||
Total property and equipment | 1,424 | 1,297 | |
Internal-use software development costs | |||
Property and Equipment [Line Items] | |||
Total property and equipment | 217,764 | 212,913 | |
Capitalized computer software additions | 4,500 | $ 8,100 | |
Leasehold improvements | |||
Property and Equipment [Line Items] | |||
Total property and equipment | $ 1,035 | $ 1,052 |
Goodwill and Intangible Assets, Net - Narrative (Details) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Oct. 31, 2023
reportingUnit
|
Mar. 31, 2024
USD ($)
|
Mar. 31, 2023
USD ($)
|
|
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Number of reporting units | reportingUnit | 1 | ||
Amortization of intangible assets | $ | $ 22.0 | $ 21.1 |
Goodwill and Intangible Assets, Net - Schedule of Change in Goodwill (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Goodwill [Roll Forward] | ||
Balance as of beginning of period | $ 1,116,542 | $ 722,774 |
Goodwill acquired | 0 | 395,164 |
Foreign currency translation | (3) | 7 |
Balance as of end of period | $ 1,116,539 | $ 1,117,945 |
Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
|
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 1,041,260 | $ 1,039,920 |
Accumulated Amortization | 309,915 | 287,911 |
Total future amortization of intangible assets | $ 731,345 | $ 752,009 |
Corporate trade name | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted- Average Remaining Useful Life | 9 months 18 days | 1 year |
Gross Carrying Amount | $ 51,965 | $ 51,965 |
Accumulated Amortization | 35,954 | 30,288 |
Total future amortization of intangible assets | $ 16,011 | $ 21,677 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted- Average Remaining Useful Life | 14 years 2 months 12 days | 14 years 6 months |
Gross Carrying Amount | $ 806,668 | $ 806,668 |
Accumulated Amortization | 150,928 | 139,150 |
Total future amortization of intangible assets | $ 655,740 | $ 667,518 |
Technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted- Average Remaining Useful Life | 3 years 6 months | 3 years 9 months 18 days |
Gross Carrying Amount | $ 162,015 | $ 162,015 |
Accumulated Amortization | 105,495 | 101,566 |
Total future amortization of intangible assets | $ 56,520 | $ 60,449 |
Below market lease, net | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted- Average Remaining Useful Life | 0 years | 0 years |
Gross Carrying Amount | $ 1,218 | $ 1,218 |
Accumulated Amortization | 1,218 | 1,218 |
Total future amortization of intangible assets | $ 0 | $ 0 |
Provider network contracts | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted- Average Remaining Useful Life | 1 year 6 months | 1 year 1 month 6 days |
Gross Carrying Amount | $ 19,394 | $ 18,054 |
Accumulated Amortization | 16,320 | 15,689 |
Total future amortization of intangible assets | $ 3,074 | $ 2,365 |
Goodwill and Intangible Assets, Net - Schedule of Future Estimated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2024 | $ 65,129 | |
2025 | 63,288 | |
2026 | 63,038 | |
2027 | 60,296 | |
2028 | 48,362 | |
Thereafter | 431,232 | |
Total future amortization of intangible assets | $ 731,345 | $ 752,009 |
Long-term Debt - Schedule of Convertible Debt (Details) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024
USD ($)
shares
$ / shares
|
Dec. 31, 2023
USD ($)
|
Oct. 31, 2018
USD ($)
|
|
2029 Notes | |||
Debt Instrument [Line Items] | |||
Debt issuance costs | $ 11,600 | ||
Senior Notes | 2025 Notes | |||
Debt Instrument [Line Items] | |||
Aggregate principal amount at issuance | $ 172,500 | $ 172,500 | |
Interest rate | 1.50% | 1.50% | |
Debt issuance costs | $ 5,929 | ||
Net proceeds | $ 166,571 | ||
Conversion price (in dollars per share) | $ / shares | $ 33.43 | ||
Shares issuable upon conversion (in shares) | shares | 5,160 | ||
Carrying value | $ 170,494 | ||
Unamortized debt discount and issuance costs | 2,006 | ||
Outstanding principal | $ 172,500 | ||
Remaining amortization period (years) | 1 year 6 months | ||
Senior Notes | 2025 Notes | Level 2 | |||
Debt Instrument [Line Items] | |||
Fair value | $ 194,911 | ||
Senior Notes | 2029 Notes | |||
Debt Instrument [Line Items] | |||
Aggregate principal amount at issuance | $ 402,500 | $ 402,500 | |
Interest rate | 3.50% | ||
Debt issuance costs | $ 11,598 | ||
Net proceeds | $ 390,902 | ||
Conversion price (in dollars per share) | $ / shares | $ 38.00 | ||
Shares issuable upon conversion (in shares) | shares | 10,592 | ||
Carrying value | $ 391,503 | ||
Unamortized debt discount and issuance costs | 10,997 | ||
Outstanding principal | $ 402,500 | ||
Remaining amortization period (years) | 5 years 8 months 12 days | ||
Senior Notes | 2029 Notes | Level 2 | |||
Debt Instrument [Line Items] | |||
Fair value | $ 440,637 |
Long-term Debt - Narrative (Details) shares in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|
Aug. 02, 2023 |
Jan. 20, 2023
USD ($)
day
|
Aug. 01, 2022
USD ($)
|
Dec. 31, 2023
USD ($)
|
Oct. 31, 2018
USD ($)
|
Mar. 31, 2024
USD ($)
shares
|
Dec. 31, 2023
USD ($)
shares
|
Oct. 13, 2023
USD ($)
|
Aug. 31, 2020
USD ($)
|
|
Debt Instrument [Line Items] | |||||||||
Commitment fee percentage | 0.50% | ||||||||
Line of Credit | Secured Debt | |||||||||
Debt Instrument [Line Items] | |||||||||
Maximum borrowing capacity | $ 240,000,000 | $ 175,000,000 | |||||||
Closing fee percentage | 3.00% | 2.00% | |||||||
Number of days prior to any junior debt maturity | day | 91 | ||||||||
Line of Credit | Secured Debt | Secured Overnight Financing Rate (SOFR) | |||||||||
Debt Instrument [Line Items] | |||||||||
Basis spread on variable rate | 6.00% | ||||||||
Line of Credit | Secured Debt | Base Rate | |||||||||
Debt Instrument [Line Items] | |||||||||
Basis spread on variable rate | 5.00% | ||||||||
Line of Credit | Revolving Credit Facility | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 415,000,000 | ||||||||
Maximum borrowing capacity | $ 25,000,000 | $ 50,000,000 | |||||||
Closing fee percentage | 3.00% | 2.00% | |||||||
Repayments of long-term lines of credit | 434,800,000 | ||||||||
Cash paid for interest | 9,100,000 | ||||||||
Prepayment premium | 10,700,000 | ||||||||
Outstanding principal | 37,500,000 | ||||||||
Line of Credit | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) | |||||||||
Debt Instrument [Line Items] | |||||||||
Basis spread on variable rate | 4.00% | ||||||||
Line of Credit | Revolving Credit Facility | Base Rate | |||||||||
Debt Instrument [Line Items] | |||||||||
Basis spread on variable rate | 3.00% | ||||||||
Line of Credit | 2022 Credit Agreement | |||||||||
Debt Instrument [Line Items] | |||||||||
Prepayment penalty prior to first anniversary of closing date (in percent) | 3.00% | ||||||||
Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent) | 2.00% | ||||||||
Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent) | 1.00% | ||||||||
Prepayment penalty on or after third anniversary of closing date (in percent) | 0.00% | ||||||||
2024 Notes | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 117,100,000 | ||||||||
Interest rate | 3.50% | ||||||||
Long-term debt, net | $ 0 | ||||||||
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount | 100.00% | ||||||||
Aggregate principal amount | $ 23,300,000 | ||||||||
Debt conversion issued (in shares) | shares | 1,300 | ||||||||
Repayments of debt | $ 1,000,000 | ||||||||
2024 Notes | Senior Notes | Common Class A | Class A Common Stock | |||||||||
Debt Instrument [Line Items] | |||||||||
Conversion rate per $1,000 of principal | 0.0556153 | ||||||||
2025 Notes | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 172,500,000 | $ 172,500,000 | |||||||
Interest rate | 1.50% | 1.50% | |||||||
Conversion amount (in shares) | shares | 5,160 | ||||||||
Conversion rate per $1,000 of principal | 0.0299135 | ||||||||
Debt issuance costs | $ 5,929,000 | ||||||||
Unamortized debt discount and issuance costs | $ 2,006,000 | ||||||||
3.50% Convertible Senior Notes Due 2029 | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 402,500,000 | $ 402,500,000 | |||||||
Interest rate | 3.50% | 3.50% | |||||||
Senior Convertible Notes Due 2029 And 2025 | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Conversion amount (in shares) | shares | 20,300 | ||||||||
Senior Convertible Notes | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt instrument, repurchase price due to fundamental change as percentage of principal amount | 100.00% | ||||||||
Repurchase covenant, sale price as a percentage of conversion price | 130.00% | ||||||||
Repurchase covenant, trading days, minimum | 20 days | ||||||||
Consecutive trading days, minimum | 30 days | ||||||||
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price | 100.00% | ||||||||
2029 Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt issuance costs | $ 11,600,000 | $ 11,600,000 | |||||||
2029 Notes | Senior Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 402,500,000 | $ 402,500,000 | 402,500,000 | ||||||
Interest rate | 3.50% | ||||||||
Conversion amount (in shares) | shares | 10,592 | ||||||||
Conversion rate per $1,000 of principal | 0.0263125 | ||||||||
Debt instrument, issue price, percentage | 100.00% | ||||||||
Proceeds from secured lines of credit | $ 390,900,000 | ||||||||
Debt issuance costs | $ 11,598,000 | ||||||||
Unamortized debt discount and issuance costs | $ 10,997,000 | ||||||||
2022 Credit Agreement | Line of Credit | Revolving Credit Facility | |||||||||
Debt Instrument [Line Items] | |||||||||
Repayments of long-term lines of credit | 37,500,000 | ||||||||
2022 Credit Agreement | Line of Credit | Term Loan Facility | |||||||||
Debt Instrument [Line Items] | |||||||||
Repayments of long-term lines of credit | $ 415,000,000 | ||||||||
2022 Credit Agreement | Secured Debt | |||||||||
Debt Instrument [Line Items] | |||||||||
Unamortized debt discount and issuance costs | $ 14,600,000 |
Long-term Debt - Schedule of Debt (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Debt Instrument [Line Items] | ||
Amortization of Debt Issuance costs | $ 882 | $ 911 |
Total Exp | 5,997 | 12,895 |
2029 Notes | Senior Notes | ||
Debt Instrument [Line Items] | ||
Interest Expense | 3,522 | |
Amortization of Debt Issuance costs | 480 | |
Total Exp | 4,002 | |
2022 Credit Agreement | Line of Credit | ||
Debt Instrument [Line Items] | ||
Interest Expense | 946 | 11,124 |
Amortization of Debt Issuance costs | 79 | 544 |
Total Exp | 1,025 | 11,668 |
2024 Notes | Senior Notes | ||
Debt Instrument [Line Items] | ||
Interest Expense | 213 | |
Amortization of Debt Issuance costs | 46 | |
Total Exp | 259 | |
2025 Notes | Senior Notes | ||
Debt Instrument [Line Items] | ||
Interest Expense | 647 | 647 |
Amortization of Debt Issuance costs | 323 | 321 |
Total Exp | $ 970 | $ 968 |
Commitments and Contingencies - Narrative (Details) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024
USD ($)
customer
|
Dec. 31, 2023
USD ($)
|
Mar. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
|
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Automatic extension period | 1 year | |||
Automatic extension after each period | 1 year | |||
Percent of tax savings to be paid | 85.00% | |||
Tax receivables agreement liability | $ 108,105 | $ 107,932 | ||
Percentage of cash and cash equivalents held with FDIC participating bank | 98.60% | |||
Total restricted cash and restricted investments | $ 233,478 | 223,457 | $ 191,970 | $ 215,158 |
Percentage of cash held in international banks | 1.40% | |||
UPMC Reseller Agreement | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Number of customers | customer | 20 | |||
Letter of Credit | Line of Credit | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Maximum borrowing capacity | $ 18,000 | 17,900 | ||
Letter of Credit | Line of Credit | Collateral with financial institutions | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Restricted funds | $ 18,600 | $ 18,400 |
Commitments and Contingencies - Schedule of Credit and Concentration Risk (Details) - Customer Concentration Risk |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Cook County Health and Hospitals System | Accounts Receivable | Trade Accounts Receivable | ||
Concentration Risk [Line Items] | ||
Concentration risk | 43.30% | 46.90% |
Cook County Health and Hospitals System | Revenues | ||
Concentration Risk [Line Items] | ||
Concentration risk | 11.40% | 17.20% |
Center for Medicare & Medicaid Services | Accounts Receivable | Trade Accounts Receivable | ||
Concentration Risk [Line Items] | ||
Concentration risk | 10.60% | |
Humana Insurance Company | Revenues | ||
Concentration Risk [Line Items] | ||
Concentration risk | 21.60% | |
Florida Blue Medicare, Inc. | Revenues | ||
Concentration Risk [Line Items] | ||
Concentration risk | 12.70% | 11.90% |
Molina Healthcare, Inc. | Revenues | ||
Concentration Risk [Line Items] | ||
Concentration risk | 11.20% | 13.20% |
Leases - Narrative (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 27, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
option
payment
|
Dec. 31, 2023
USD ($)
payment
|
|
Lessee, Lease, Description [Line Items] | |||
Number of leases option | option | 1 | ||
Loss on termination of lease | $ 3,500 | $ 6,500 | |
Number of lease termination payment | payment | 2 | 2 | |
Termination payment paid | $ 3,500 | $ 3,250 | $ 3,250 |
Lease Agreements | |||
Lessee, Lease, Description [Line Items] | |||
Letters of credit outstanding, amount | 2,200 | 2,100 | |
Restricted funds | $ 2,200 | $ 2,100 |
Leases - Schedule of Primary Office Leases (Details) $ in Thousands |
Mar. 31, 2024
USD ($)
|
---|---|
Lessee, Lease, Description [Line Items] | |
Future Minimum Lease Commitments | $ 54,119 |
VIRGINIA | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 6 years 9 months 18 days |
Future Minimum Lease Commitments | $ 3,258 |
Letter of Credit Amount Required | $ 1,579 |
Edison, NJ | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 2 years 1 month 6 days |
Future Minimum Lease Commitments | $ 1,104 |
Letter of Credit Amount Required | $ 222 |
Makati City, Philippines | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 4 years 2 months 12 days |
Future Minimum Lease Commitments | $ 2,825 |
Letter of Credit Amount Required | $ 0 |
Alpharetta, GA | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 1 year 6 months |
Future Minimum Lease Commitments | $ 716 |
Letter of Credit Amount Required | $ 0 |
Pune, India | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 4 years |
Future Minimum Lease Commitments | $ 2,334 |
Letter of Credit Amount Required | $ 0 |
Brea, CA | |
Lessee, Lease, Description [Line Items] | |
Lease Termination Term (in years) | 3 years 2 months 12 days |
Future Minimum Lease Commitments | $ 3,083 |
Letter of Credit Amount Required | $ 0 |
Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Leases [Abstract] | ||
Operating lease cost | $ 103 | $ 1,940 |
Variable lease cost | 1,425 | 1,556 |
Total lease cost | $ 1,528 | $ 3,496 |
Leases - Schedule of Maturity of Lease Liabilities (Details) $ in Thousands |
Mar. 31, 2024
USD ($)
|
---|---|
Leases [Abstract] | |
2024 | $ 13,024 |
2025 | 8,338 |
2026 | 7,566 |
2027 | 6,955 |
2028 | 5,808 |
Thereafter | 12,428 |
Total lease payments | 54,119 |
Less: | |
Interest | 8,954 |
Present value of lease liabilities | $ 45,165 |
Leases - Schedule of Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details) |
Mar. 31, 2024 |
---|---|
Leases [Abstract] | |
Weighted average discount rate | 7.07% |
Weighted average remaining lease term | 5 years 1 month 6 days |
Convertible Preferred Equity - Narratives (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions |
3 Months Ended | |||
---|---|---|---|---|
Jan. 20, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Temporary Equity [Line Items] | ||||
Issuance of series A preferred stock, net of issuance costs (in shares) | 175 | |||
Preferred class A common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | ||
Class A common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | ||
Series A Preferred Stock | ||||
Temporary Equity [Line Items] | ||||
Issuance of series A preferred stock, net of issuance costs (in shares) | 175 | |||
Preferred class A common stock, par value (in dollars per share) | $ 0.01 | |||
Purchase price (in dollars per share) | $ 960.00 | |||
Gross proceeds from sale of temporary equity | $ 168.0 | |||
Liquidation preference (in dollars per share) | $ 1,000 | |||
Annual increase in dividend rate | 2.00% | |||
Conversion price (in dollar per share) | $ 40.00 | |||
Accretion of Series A preferred stock | $ 2.9 | |||
Series A Preferred Stock | Called by company on or after January 20, 2025 | ||||
Temporary Equity [Line Items] | ||||
Redemption price percentage | 165.00% | |||
Series A Preferred Stock | Called by holder on or after January 20, 2030 | ||||
Temporary Equity [Line Items] | ||||
Redemption price percentage | 150.00% | |||
Series A Preferred Stock | Refinancing or replacement of debt | ||||
Temporary Equity [Line Items] | ||||
Redemption price percentage | 165.00% | |||
Series A Preferred Stock | Change of control prior to January 20, 2025 | ||||
Temporary Equity [Line Items] | ||||
Redemption price percentage | 150.00% | |||
Series A Preferred Stock | Change of control after January 20, 2025 | ||||
Temporary Equity [Line Items] | ||||
Redemption price percentage | 135.00% | |||
Series A Preferred Stock | Secured Overnight Financing Rate (SOFR) | ||||
Temporary Equity [Line Items] | ||||
Quarterly dividend rate, basis spread on variable rate | 6.00% | |||
Common Class A | ||||
Temporary Equity [Line Items] | ||||
Class A common stock, par value (in dollars per share) | $ 0.01 |
Convertible Preferred Equity - Schedule Of Paid Dividends (Details) - USD ($) |
3 Months Ended | |||
---|---|---|---|---|
Mar. 28, 2024 |
Mar. 28, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Dividends Payable [Line Items] | ||||
Total Amount Paid | $ 5,078,000 | $ 3,651,000 | ||
Series A Preferred Stock | ||||
Dividends Payable [Line Items] | ||||
Dividends paid (in dollars per share) | $ 29.02 | $ 20.86 | ||
Total Amount Paid | $ 5,078,500 | $ 3,650,500 |
Loss Per Common Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Earnings Per Share [Abstract] | ||
Loss before preferred dividends and accretion of Series A Preferred Stock | $ (17,280) | $ (19,982) |
Dividends and accretion of Series A Preferred Stock | (7,945) | (6,276) |
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic | (25,225) | (26,258) |
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted | $ (25,225) | $ (26,258) |
Weighted-average common shares outstanding - basic (in shares) | 114,141 | 107,783 |
Weighted-average common shares outstanding - diluted (in shares) | 114,141 | 107,783 |
Basic and diluted: | ||
Basic (in dollars per share) | $ (0.22) | $ (0.24) |
Diluted (in dollars per share) | $ (0.22) | $ (0.24) |
Loss Per Common Share -Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 26,259 | 13,746 |
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 1,222 | 1,923 |
Stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 410 | 1,260 |
Series A Preferred Stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 4,375 | 4,375 |
Convertible senior notes | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 20,252 | 6,188 |
Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | $ 18,786 | $ 10,710 |
Cost of revenue | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | 1,005 | 1,540 |
Selling, general and administrative expenses | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | 17,781 | 9,170 |
Stock options | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | 0 | 60 |
RSUs | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | 7,468 | 7,489 |
PSUs | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | 11,318 | 2,877 |
LSUs | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total compensation expense by financial statement line item | $ 0 | $ 284 |
Stock-based Compensation - Narrative (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Share-Based Payment Arrangement [Abstract] | ||
Stock-based compensation capitalized | $ 0 | $ 0 |
Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details) - shares shares in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
RSUs | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Granted (in shares) | 955 | 996 |
PSUs | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Granted (in shares) | 808 | 424 |
Income Taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Income Tax Disclosure [Abstract] | ||
Provision for (benefit from) income taxes | $ 565 | $ (68,189) |
Effective tax rate | (3.40%) | 77.30% |
Unrecognized tax benefits | $ 2,700 | |
Amount of tax benefit percent | 85.00% |
Investments and Equity Method Investees (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Schedule of Equity Method Investments [Line Items] | |||
Gain from equity method investees | $ 306 | $ 423 | |
Investments in equity method carrying amount | 8,197 | $ 4,895 | |
Equity Method Investee | Services Agreements | |||
Schedule of Equity Method Investments [Line Items] | |||
Revenue related to services agreements | 3,800 | $ 4,800 | |
Investments in equity method carrying amount | 3,000 | ||
Related party | Services Agreements | |||
Schedule of Equity Method Investments [Line Items] | |||
Revenue related to services agreements | $ 3,000 | ||
Minimum | |||
Schedule of Equity Method Investments [Line Items] | |||
Economic interest percentage | 4.00% | 4.00% | |
Voting interest percentage | 25.00% | ||
Maximum | |||
Schedule of Equity Method Investments [Line Items] | |||
Economic interest percentage | 34.00% | 34.00% | |
Voting interest percentage | 34.00% |
Fair Value Measurement - Schedule of Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Liabilities | ||
Contingent consideration | $ 88,753 | $ 83,600 |
Total fair value of liabilities measured on a recurring basis | 88,753 | 83,600 |
Level 1 | ||
Liabilities | ||
Contingent consideration | 0 | 0 |
Total fair value of liabilities measured on a recurring basis | 0 | 0 |
Level 2 | ||
Liabilities | ||
Contingent consideration | 0 | 0 |
Total fair value of liabilities measured on a recurring basis | 0 | 0 |
Level 3 | ||
Liabilities | ||
Contingent consideration | 88,753 | 83,600 |
Total fair value of liabilities measured on a recurring basis | $ 88,753 | $ 83,600 |
Fair Value Measurement - Schedule of Changes in Contingent Consideration Measured at Fair Value (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Balance as of beginning of period | $ 83,600 | $ 78,000 |
Additions | 0 | 69,761 |
Settlements | (3,755) | (29,961) |
Total (gain) loss, net | 8,908 | 4,300 |
Balance as of end of period | $ 88,753 | $ 122,100 |
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag | Change in fair value of contingent consideration | Change in fair value of contingent consideration |
Fair Value Measurement - Schedule of Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value | $ 88,753 | $ 83,600 |
Level 3 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value | $ 88,753 | $ 83,600 |
Level 3 | Contractual terms | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Assumption or input ranges | 88,753 | |
Level 3 | Risk-neutral expected earnout consideration | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Assumption or input ranges | 83,600 |
Related Parties - Assets and Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
||
---|---|---|---|---|
Assets [Abstract] | ||||
Accounts receivable, net | [1] | $ 427,739 | $ 446,749 | |
Liabilities | ||||
Accounts payable | [1] | 77,346 | 48,246 | |
Related party | ||||
Assets [Abstract] | ||||
Accounts receivable, net | 3,666 | 8,045 | ||
Liabilities | ||||
Accounts payable | $ 541 | $ 390 | ||
|
Related Parties - Revenues and Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Expenses | ||||
Selling, general and administrative expenses | [1] | $ 79,104 | $ 89,726 | |
Related party | ||||
Related Party Transaction [Line Items] | ||||
Revenue | 30,784 | 54,721 | ||
Expenses | ||||
Cost of revenue | 26,914 | 47,506 | ||
Selling, general and administrative expenses | $ 0 | $ 242 | ||
|
Repositioning and Other Changes - Narrative (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Repositioning Plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected cost of restructuring | $ 48,800 | $ 48,776 |
Repositioning and Other Changes - Schedule of Costs Associated with the Repositioning Plan (Details) - Repositioning Plan - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | $ 9,929 | $ 45,166 | |
Expected cost of restructuring | 48,800 | $ 48,776 | |
Severance and termination benefits | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | 1,804 | 10,368 | |
Expected cost of restructuring | 12,368 | ||
Dedicated employee costs | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | 1,185 | 8,085 | |
Expected cost of restructuring | 8,229 | ||
Professional services | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | 3,488 | 16,399 | |
Expected cost of restructuring | 17,865 | ||
Office space consolidation | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring charges | $ 3,452 | $ 10,314 | |
Expected cost of restructuring | $ 10,314 |
Reserves for Claims and Performance-Based Arrangements - Schedule of Activity in Claims Reserves and Performance - Based Arrangements (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Balance, beginning of period | $ 404,048 | $ 199,730 |
Incurred health care costs: | ||
Current year to date period | 374,879 | 180,675 |
Prior year to date period | (15,186) | (19,914) |
Total claims incurred | 359,693 | 160,761 |
Claims paid related to: | ||
Current year to date period | (146,399) | (64,870) |
Prior year to date period | (248,703) | (98,424) |
Total claims paid | (395,102) | (163,294) |
Balance, end of period | $ 368,639 | $ 197,197 |
Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Supplemental Disclosure of Non-cash Investing and Financing Activities | ||
Accrued property and equipment purchases | $ (34) | $ 30 |
Class A common stock issued in connection with business combinations | 0 | 261,271 |
Accrued net working capital adjustment with business combinations | 2,712 | 1,098 |
Effects of Leases | ||
Operating cash flows from operating leases | (3,253) | 3,528 |
Leased assets disposed of (obtained in) exchange for operating lease liabilities | $ (185) | $ (3,076) |
I"6\S\NS0I1R! APH !@ !X;"]W;W)K
HFX=Y1PT$D# ULOI%;2/
M8PBNT3AY;PGU$*%;BX/LY0OV(>EXI/\+=D_@N&!(I.QF-F<_]6[ "6=C'!L:
M4)W-KJ
1%FDRD]QX2;PW59=DTGF,6*O%/Z2\Y\R\$'
MZIW$[44ZFH9D==FO1N/9Y9,>0I"4BPN8C,.D*-QB&J:SPF?'71Z3CU"REA,"
M):>"BR(:47,0PO AP$B0
M0U6GMT0"4$Y(X#5W,B/,A;^%B;>C5.C;<>7:5A;8 ]F,'$STZ(8$9DN%=.&P
M D:61">A"HH6.*A,KC.RWY7,B7QR8C#8.AX*"$E2698TXD[FM:I8VD TSMB_
M?%X9<2N!=]3*#(E@D5$D80@8>*/@LH7904= E" H!5"T+ AK:BHD[?()0]A;%:UHAK*N5].]E0'JVYLG$1J +*=EMJ CMV(RSU9EF9
M!=(8L)+'^P9L>\%(_=8X\8[WTAL2^JV ++8O-"WD4-84VK6ZGI++(3-P(Q>3
M(P3"T9?&\#CYJ\F7LH+3)$,\47&.^VL6++Y]31DK;L7WU#Z,(9*6TSKIS=O6
M80*57I()9<$],X\UE;D&E^UNY"H[T\)^AF$+P^6!-JX+L5H8@Q^ICY0U3IK4
M_CGA.:@0#D6RCR,IS778I9<@CUVRKSTB%+](KLU[@!''GF>9G/&S! 298+Q8
MBP0OD I\,TC%1.HH39G=]]J6M:XV7(Z3%^?^,22M![]!K3J0-,6$@1#_[*5Z
MQPG:\9"N0;<-L>T GVU 4_VUI_0UZ!#$ F\DV.X>#)P&>Q3(G^DT%O80S'=3H2T3&YAG-Z#(P[
MQT@]')-[.&B>T)WD%EU .6PP@B5QMABO]R-&\8^0-::!ME2N8&\6Q]M!VXW&
M]6@#XZ$%QGM1+,V7J7*C-_I1%K_6'WG]\<0]A,0FMW3P++"5Q'A8?7QAVV.3
M$5 <[:T@ML2U#&/,DTD.* [Y#D2U*%J(2@WL*8YF*U$M\3O+!>;(,)Y:&'\@
M32TRU!W9:$H-X:F%\(?1M%2ITW3DP41KABDU,*K]N?J(Y@F9T _R\J]#D .&^#VH
MD^U@!?)PI>.%DS[PZ.7&-8_(1TRT,A/(9"=*JM19NP+^2HS/9CG-4\Y@6&K*
M#J(/DU3>VU$-:XR:/^7UQT!3_<)A$#/(7,/6;BD>DF)HC]1]MOW
,C11X]1
MN\6MC4FUM\/PPD%[,H[L
MMO-YR/[1:_)[-=?T5H)%[@8\V]GTOGL@WW# '"@DUW=(73FFNV&D+D@$(/.]
M9(VT]
+4T"OJE"1J&@:'937#*EBH3%;DXA$Q&C)Z_;?$_43 GQ4HZ)>>:
M6IJ3_A3BR@9&C%Q@+%U[[%ZC#;$[%@5D@+'AA(7#]/\7YOI[XLR^0G(V%'ZM
MI59!\M2*(/'.$4L+"]!C'8=X*5VNS#)J,C''^[#V5Y)APK9D-69^X-Q;6;TB
MKFV,&YC:H>^B02Q;*O)$Y3_E\,E,O4-<'VRM:46N?YBUS'1,G;N)!V 15$
M;BGM+.2*CF;:+LNB!0Q[R]1TC>4JCSH.:H.IX*KP[#KC)].W
*DAG$EY
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M> /6"VM#_X,#;"[>%_\"4$L#!!0 ( #B1J5@K=S!IF @ +X6 9
M>&PO=V]R:W-H965T
MJBR[ZHT)R*B)]=B
M?"YXAK*FTJDXDXTW/\KLMX9*F12<"PIOX\AZHKD -KH?PM"ASSOR;J&Z9E5J
M%R8[6 #*F9Z#'LH51.6ZYJ#.SMG"4G\)"6BR)O7'Q?G#=XO)^.HG5+DI=/H_
MQZJC?(H:MJ'T!1(5[@NT]=*I>+1"\\QB[6#*!)_LD;W,U!0NR/?XS2(WU505
MS#J=#"B*L>]VM#4?Q+Q0>TQ0A\7^1>)V]1!3!X7!/%32,$990.RT[_+LSZEO
M